睿知中国医院研究地图
候选清单

武汉华中科技大学同济医学院

华中科技大学同济医学院附属同济医院

Tongji Hospital

在本站收录的 53 种疾病中,这家医院列在其中 41 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

华中科技大学同济医学院附属同济医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma8 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma10 篇牵头论文牵头 2 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma238 篇牵头论文牵头 23 项开放试验
  4. 胃癌Stomach cancer45 篇牵头论文牵头 4 项开放试验
  5. 肝母细胞瘤Hepatoblastoma0 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  7. 脊索瘤Chordoma1 篇牵头论文
  8. 骨肉瘤Osteosarcoma12 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour3 篇牵头论文牵头 1 项开放试验
  10. 神经母细胞瘤Neuroblastoma8 篇牵头论文
  11. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  12. 多发性骨髓瘤Multiple myeloma19 篇牵头论文牵头 3 项开放试验
  13. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia7 篇牵头论文牵头 1 项开放试验
  14. 再生障碍性贫血Aplastic anaemia8 篇牵头论文
  15. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis20 篇牵头论文牵头 1 项开放试验
  16. β 地中海贫血Beta thalassaemia0 篇牵头论文
  17. 血友病 AHaemophilia A4 篇牵头论文
  18. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura6 篇牵头论文
  19. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder18 篇牵头论文牵头 7 项开放试验
  20. IgG4相关性疾病IgG4-related disease11 篇牵头论文牵头 2 项开放试验
  21. 重症肌无力Myasthenia gravis17 篇牵头论文牵头 8 项开放试验
  22. 烟雾病Moyamoya disease3 篇牵头论文牵头 1 项开放试验
  23. 胆道闭锁Biliary atresia2 篇牵头论文牵头 1 项开放试验
  24. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  25. 特发性肺纤维化Idiopathic pulmonary fibrosis14 篇牵头论文
  26. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis1 篇牵头论文
  27. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis11 篇牵头论文牵头 1 项开放试验
  28. 法布雷病Fabry disease0 篇牵头论文
  29. 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
  30. 白塞病Behçet disease1 篇牵头论文
  31. Alport 综合征Alport syndrome2 篇牵头论文
  32. IgA 肾病IgA nephropathy21 篇牵头论文
  33. 戈谢病Gaucher disease0 篇牵头论文
  34. 尼曼-匹克病 C 型Niemann–Pick disease type C0 篇牵头论文
  35. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  36. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  37. 先天性巨结肠Hirschsprung disease13 篇牵头论文
  38. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa0 篇牵头论文
  39. 遗传性血管性水肿Hereditary angioedema1 篇牵头论文
  40. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
  41. Leber 遗传性视神经病变Leber hereditary optic neuropathy2 篇牵头论文

未列出的收录疾病:非典型溶血性尿毒症综合征、范可尼贫血、肝豆状核变性、大动脉炎、肝包虫病、脊髓性肌萎缩症、庞贝病、原发性硬化性胆管炎、先天性膈疝、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 4420222023: 2220232024: 1120242025: 002025

武汉有 6 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  2. 正在招募
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    分期
    II期
    开始
    2025-04
    登记号
    NCT06839066

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙

  3. 正在招募
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    分期
    III期
    开始
    2025-11
    登记号
    NCT07328841

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心中山、南宁、广州、梧州、武汉、汕头、珠海、长沙

  4. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题诱导/同步化疗
论文中的科室肿瘤内科耳鼻喉/头颈外科神经内科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma.2024PeerJ免费全文
  2. Nasopharyngeal Carcinoma Subtype Discovery via Immune Cell Scores from Tumor Microenvironment.2023Journal of immunology research免费全文
  3. Ginsenoside Rg3 Sensitizes Nasopharyngeal Carcinoma Cells to Radiation by Suppressing Epithelial Mesenchymal Transition.2023Radiation research
  4. CircSOX9 acts as a molecular sponge of miR-485-3p to promote the progression of nasopharyngeal carcinoma.2022Aging免费全文
  5. MEX3A promotes nasopharyngeal carcinoma progression via the miR-3163/SCIN axis by regulating NF-κB signaling pathway.2022Cell death & disease免费全文
  6. MiR196a-5p in extracellular vesicles released from human nasopharyngeal carcinoma enhance the phagocytosis and secretion of microglia by targeting ROCK1.2022Experimental cell research
  7. Inhibition of PDK1 enhances radiosensitivity and reverses epithelial-mesenchymal transition in nasopharyngeal carcinoma.2022Head & neck
  8. Induction of interleukin-6 by irradiation and its role in epithelial mesenchymal transition and radioresistance of nasopharyngeal carcinoma cells.2021Head & neck
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy正在招募NCT07328841研究中心III期2025-11 启动
  2. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  3. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy正在招募NCT06839066研究中心II期2025-04 启动
  4. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  5. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)进行中,不再招募NCT05587374研究中心III期2023-08 启动
  6. KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial状态不明NCT06097793研究中心早期I期2023-12 启动
  7. Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma进行中,不再招募NCT05979961研究中心III期2023-09 启动
  8. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma进行中,不再招募NCT04907370研究中心III期2021-08 启动
  9. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT03427827研究中心III期2018-07 启动
  10. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  11. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  12. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma状态不明NCT02633176研究中心III期2015-01 启动
  13. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma状态不明NCT02944708研究中心III期2015-10 启动
  14. The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT状态不明NCT01817023研究中心III期2013-04 启动
PubMed 以外找到的论文(未计入)6
  1. Development and Validation of a Multi‐Omics Model Integrating MR Radiomics and Immune Scores for Prognostic Prediction in Locally Advanced Nasopharyngeal Carcinoma2025Flavour and Fragrance Journal论文
  2. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncology论文
  3. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncology会议摘要
  4. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  5. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncology会议摘要
  6. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.3%。

牵头论文
10
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 5520232024: 0020242025: 112025

武汉有 5 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
    分期
    未注明
    开始
    2025-03
    登记号
    NCT07088354

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  2. 正在招募
    Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-01
    登记号
    NCT07699185

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗免疫治疗分子标志物与基因
论文中的科室肿瘤内科
牵头的论文10
  1. Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma.2025Cancer immunology, immunotherapy : CII免费全文
  2. SLC43A2 and NFκB signaling pathway regulate methionine/cystine restriction-induced ferroptosis in esophageal squamous cell carcinoma via a feedback loop.2023Cell death & disease免费全文
  3. BBOX1-AS1 Activates Hedgehog Signaling Pathway to Facilitate the Proliferation and Stemness of Esophageal Squamous Cell Carcinoma Cells via miR-506-5p/EIF5A/PTCH1 Axis.2023Current molecular pharmacology
  4. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.2023Frontiers in immunology免费全文
  5. Long intergenic non-protein coding RNA 00858 participates in the occurrence and development of esophageal squamous cell carcinoma through the activation of the FTO-m6A-MYC axis by recruiting ZNF184.2023Genomics
  6. Diagnosis and treatment of right ventricular metastasis from esophageal squamous cell carcinoma: An unusual case report and a literature review.2023Medicine免费全文
  7. Research Progress on the Predicting Factors and Coping Strategies for Postoperative Recurrence of Esophageal Cancer.2022Cells免费全文
  8. Esophagus cancer and essential trace elements.2022Frontiers in public health免费全文
  9. GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis.2022Oncogene免费全文
  10. An extremely atypical presentation of esophageal squamous cell carcinoma with pancreatic and hepatic metastases: A case report and overview of the literature.2021Medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy正在招募NCT07088354牵头方2025-03 启动
  2. Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma正在招募NCT07699185牵头方II期2024-01 启动
  3. Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma已完成NCT07705412牵头方2025-09 启动
  4. Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study状态不明NCT05028231牵头方2021-06 启动
  5. Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma进行中,不再招募NCT06165380牵头方(推断)II期2023-10 启动
  6. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma已完成NCT03469557研究中心II期2017-07 启动
  7. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  8. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  9. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial状态不明NCT02319187研究中心III期2014-12 启动
PubMed 以外找到的论文(未计入)15
  1. Tislelizumab combined with radiotherapy for unresectable locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase II study (TREC)2025Research Square预印本
  2. Letter to the Editor: Human papillomavirus 16 infection in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy2024未列出期刊预印本
  3. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Square预印本
  4. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  6. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  7. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  8. miR-139-5p mediates TGIF1 to regulate the TGFβ pathway and inhibit growth of esophageal squamous cell carcinoma cells2023European surgery. Supplement/European surgery论文
  9. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  10. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  11. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  12. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  13. Design and synthesis of copper nanoparticles for the treatment of human esophageal cancer: introducing a novel chemotherapeutic supplement2022Journal of Experimental Nanoscience论文
  14. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figshare数据集
  15. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 238 篇,占 1.6%。

牵头论文
238
2021–2025 年
牵头试验
51
任何状态,ClinicalTrials.gov
牵头的开放试验
23
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 424220212022: 373720222023: 545420232024: 444420242025: 54542025

武汉有 6 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 30

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2026-04
    登记号
    NCT07413354

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  2. 正在招募
    Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
    分期
    II期
    开始
    2025-08
    登记号
    NCT06954116

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  3. 正在招募
    AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
    分期
    未注明
    开始
    2025-06
    登记号
    NCT07062380

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  4. 正在招募
    Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-12
    登记号
    NCT07154082

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  5. 正在招募
    Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
    分期
    I/II期
    开始
    2025-10
    登记号
    NCT07282184

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  6. 正在招募
    Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
    分期
    未注明
    开始
    2024-03
    登记号
    NCT06280313

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  7. 正在招募
    Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
    分期
    IV期
    开始
    2024-04
    登记号
    NCT06311929

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  8. 正在招募
    Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
    分期
    I期
    开始
    2024-06
    登记号
    NCT06470256

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  9. 正在招募
    Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
    分期
    未注明
    开始
    2024-11
    登记号
    NCT06653062

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  10. 正在招募
    Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
    分期
    未注明
    开始
    2024-10
    登记号
    NCT07838415

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  11. 正在招募
    HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2023-12
    登记号
    NCT06187961

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  12. 正在招募
    Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
    分期
    未注明
    开始
    2020-05
    登记号
    NCT05520788

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  13. 即将招募
    Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
    分期
    III期
    开始
    2026-05
    登记号
    NCT07537946

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  14. 即将招募
    Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
    分期
    不分期
    开始
    2026-04
    登记号
    NCT07537959

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  15. 即将招募
    Denosumab Strategy for Liver Cancer With Bone Metastases
    分期
    II期
    开始
    2026-05
    登记号
    NCT07537972

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  16. 即将招募
    AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07729618

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  17. 即将招募
    AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07732504

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  18. 即将招募
    QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-02
    登记号
    NCT06822985

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  19. 即将招募
    Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
    分期
    I/II期
    开始
    2025-04
    登记号
    NCT06896396

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  20. 即将招募
    Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
    分期
    II期
    开始
    2025-07
    登记号
    NCT07064668

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  21. 即将招募
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    分期
    II期
    开始
    2025-12
    登记号
    NCT07350070

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院;另有 4 家列出的医院为研究中心南宁、武汉、济南、福州、青岛

  22. 即将招募
    Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
    分期
    不分期
    开始
    2025-12
    登记号
    NCT07350824

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  23. 即将招募
    Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
    分期
    III期
    开始
    2024-06
    登记号
    NCT06089369

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  24. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  25. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  26. 正在招募
    cfDNA Methylation for Liver Cancer Recurrence Detection
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07466602

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心武汉

  27. 正在招募
    Phase 2 Study of WGI-0301 for Advanced HCC
    分期
    II期
    开始
    2024-07
    登记号
    NCT06309485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心南昌、哈尔滨、成都、杭州、武汉、长沙

  28. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  29. 正在招募
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    分期
    I期
    开始
    2023-10
    登记号
    NCT06560827

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、武汉、沈阳、福州、郑州、长沙

  30. 邀请入组
    A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
    分期
    II期
    开始
    2021-12
    登记号
    NCT05441475

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室消化/肝病科影像/核医学科肿瘤内科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文238
  1. Long-Term Survival and Beneficiaries of Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma.2026Annals of surgical oncology
  2. Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets.2026Biochimica et biophysica acta. Reviews on cancer
  3. Research progress on the regulation of microRNAs by traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma.2026Cancer treatment and research communications
  4. NEK7-induced phosphorylation of EGFR on serine 1070 drives the acquired lenvatinib resistance in hepatocellular carcinoma.2026Hepatology (Baltimore, Md.)免费全文
  5. Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study.2026International journal of surgery (London, England)
  6. Vessels encapsulating tumor clusters is associated with impaired efficacy of adjuvant immunotherapy in resected hepatocellular carcinoma.2026Journal of advanced research免费全文
  7. A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study.2026Science China. Life sciences
  8. Hafnium Metal-Organic Framework-Based Glutamine Metabolism Disruptor For Potentiating Radio-Immunotherapy in MYC-Amplified Hepatocellular Carcinoma.2025ACS applied materials & interfaces
  9. m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by Facilitating the Membrane Translocation and Activation of AKT.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  10. CKAP4 in hepatocellular carcinoma: competitive RETREG1/FAM134B binding, reticulophagy regulation, and cancer progression.2025Autophagy免费全文
  11. Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus.2025BJS open免费全文
  12. Risk factors for hepatocellular carcinoma rupture: multicentre retrospective study.2025BJS open免费全文
  13. From genes to therapy: a lipid Metabolism-Related genetic risk model predicts HCC outcomes and enhances immunotherapy.2025BMC cancer免费全文
  14. Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study.2025BMJ open免费全文
  15. The important role of myeloid-derived suppressor cells: From hepatitis to liver cancer.2025Biochimica et biophysica acta. Reviews on cancer
  16. Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma.2025Bioorganic chemistry
  17. Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation.2025Cancer biology & therapy免费全文
  18. FBXO22 promotes HCC angiogenesis and metastasis via RPS5/AKT/HIF-1α/VEGF-A signaling axis.2025Cancer gene therapy免费全文
  19. Senescent fibroblasts secrete CTHRC1 to promote cancer stemness in hepatocellular carcinoma.2025Cell communication and signaling : CCS免费全文
  20. The cancer-associated fibroblast facilitates YAP liquid-liquid phase separation to promote cancer cell stemness in HCC.2025Cell communication and signaling : CCS免费全文
  21. Targeting FAM134B-DDX3X axis inhibiting AKT signaling in hepatocellular carcinoma.2025Cell death & disease免费全文
  22. The Hippo-YAP signaling pathway promotes hepatocellular carcinoma progression by inducing FHL3 expression.2025Cell death & disease免费全文
  23. IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma.2025Cell death & disease免费全文
  24. Disrupting CCDC137-mediated LZTS2 and β-TrCP interaction in the nucleus inhibits hepatocellular carcinoma development via β-catenin and AKT.2025Cell death and differentiation免费全文
  25. Cancer-associated fibroblast-derived extracellular vesicles facilitate metastasis in hepatocellular carcinoma by delivering CTGF.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  26. Ribosomal protein L6 suppresses hepatocellular carcinoma by modulating FBXO22-mediated p53 degradation.2025Cellular signalling
  27. Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma.2025Clinical and molecular hepatology免费全文
  28. MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation.2025Clinical and molecular hepatology免费全文
  29. Oncofetal dual‑specificity phosphatase 9 drives stem-like properties through ERK1/2-PPARG-SCD axis-mediated lipid metabolism in hepatocellular carcinoma.2025Clinical and translational medicine免费全文
  30. Machine Learning-based Gene Biomarker Identification for Improving Prognosis and Therapy in Hepatocellular Carcinoma.2025Current medicinal chemistry
  31. Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma.2025Digestive diseases and sciences免费全文
  32. Adjuvant PD-1 inhibitors improve recurrence and survival outcomes in high-risk hepatocellular carcinoma patients after curative hepatectomy.2025European journal of medical research免费全文
  33. Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma.2025European journal of nuclear medicine and molecular imaging
  34. Differentiating atypical hepatocellular carcinoma from focal nodular Hyperplasia: The value of Kupffer phase imaging with Sonazoid-Contrast-Enhanced ultrasound compared to Gadodiamide-Enhanced MRI.2025European journal of radiology
  35. Synchronous hepatectomy and splenectomy for patients with BCLC stage 0/A hepatocellular carcinoma and clinically significant portal hypertension: A multicenter retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  36. Efficacy and safety of preoperative TACE in hepatocellular carcinoma beyond Milan criteria: A propensity score matching analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  37. An immune-related signature based on molecular subtypes for predicting the prognosis and immunotherapy efficacy of hepatocellular carcinoma.2025Frontiers in immunology免费全文
  38. Post-translational acylation modulates immunosuppression and immunotherapy efficacy in hepatocellular carcinoma.2025Genes and immunity
  39. E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression.2025Gut
  40. The impact of resection margin width on surgical outcomes for solitary hepatocellular carcinoma with sub-classification of microvascular invasion.2025HPB : the official journal of the International Hepato Pancreato Biliary Association
  41. Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma.2025Hepatology (Baltimore, Md.)免费全文
  42. Regulatory role of gut microbiota in immunotherapy of hepatocellular carcinoma.2025Hepatology international
  43. Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota.2025International journal of biological sciences免费全文
  44. Association between Vessels Encapsulating Tumor Clusters and Circulating Tumor Cells in Hepatocellular Carcinoma: Clinical Evidence and Risk Model Development.2025International journal of medical sciences免费全文
  45. TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway.2025Journal of hepatology
  46. EIF4A3-Mediated downregulation of circPTEN promotes hepatocellular carcinoma progression through the miR-1289/RBM38 Axis.2025Journal of molecular histology
  47. Involvement of ferroptosis in metabolic dysfunction-associated steatohepatitis-related liver diseases.2025Journal of molecular medicine (Berlin, Germany)免费全文
  48. Synthesis and Preclinical Evaluation of Dual-Specific Probe Targeting Glypican-3 and Prostate-Specific Membrane Antigen for Hepatocellular Carcinoma PET Imaging.2025Molecular pharmaceutics
  49. 18F-FDG Versus Tissue Factor-Targeted PET/CT in Longitudinal Evaluation of the Formation of DEN-Induced Rat Hepatocellular Carcinoma.2025Molecular pharmaceutics
  50. VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization.2025Nature communications免费全文
  51. Circ-PAN3 facilitates hepatocellular carcinoma growth via sponging miR-153 and upregulating cyclin D1.2025Oncology research免费全文
  52. Overexpression of ORAOV1 and its association with immunotherapy resistance in hepatocellular carcinoma.2025PeerJ免费全文
  53. Perfluorobutane-enhanced US Targeting M2 Tumor-associated Macrophages for Predicting Programmed Cell Death-1 Response in Hepatocellular Carcinoma.2025Radiology. Imaging cancer免费全文
  54. PARK7-driven IGF2BP3-K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma.2025Redox biology免费全文
  55. Riplet promotes lipid metabolism changes associated with CD8 T cell exhaustion and anti-PD-1 resistance in hepatocellular carcinoma.2025Science immunology
  56. Machine learning models for predicting postoperative peritoneal metastasis after hepatocellular carcinoma rupture: a multicenter cohort study in China.2025The oncologist免费全文
  57. 18F-5-fluoro-aminosuberic acid PET/CT imaging of oxidative-stress features during the formation of DEN-induced rat hepatocellular carcinoma.2025Theranostics免费全文
  58. Prognostic model for unresectable hepatocellular carcinoma treated with transarterial therapy plus TKIs and anti-PD-1 antibodies.2025World journal of surgical oncology免费全文
  59. Revisiting the role of local treatments in the era of targeted therapy and immunotherapy for hepatocellular carcinoma.2025World journal of surgical oncology免费全文
  60. Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review.2025World journal of surgical oncology免费全文
  61. Impact of intraperitoneal lavage with lobaplatin on survival in patients undergoing hepatectomy for ruptured hepatocellular carcinoma.2025World journal of surgical oncology免费全文
  62. "Trinity" Comprehensively Regulates the Tumor Microenvironment of Lipid-Coated CaCO3@CuO2 Nanoparticles Induces "Cuproptosis" in HCC.2024ACS applied materials & interfaces
  63. CEUS in prediction of early recurrence of hepatocellular carcinoma after curative resection and to stratify the risk of early recurrence: a retrospective observational study.2024Abdominal radiology (New York)
  64. Predicting Ki-67 expression in hepatocellular carcinoma: nomogram based on clinical factors and contrast-enhanced ultrasound radiomics signatures.2024Abdominal radiology (New York)
  65. Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  66. m6A-Dependent ITIH1 Regulated by TGF-β Acts as a Target for Hepatocellular Carcinoma Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  67. SOX12 Facilitates Hepatocellular Carcinoma Progression and Metastasis through Promoting Regulatory T-Cells Infiltration and Immunosuppression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  68. YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  69. Liver resection versus microwave ablation for solitary and small (≤ 3 cm) HCC with early recurrence in different stages of liver cirrhosis: A propensity score matching study.2024Asian journal of surgery
  70. A pathologic scoring system for predicting postoperative prognosis in patients with ruptured hepatocellular carcinoma.2024Asian journal of surgery
  71. Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  72. Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation.2024Cancer communications (London, England)免费全文
  73. GPR56 facilitates hepatocellular carcinoma metastasis by promoting the TGF-β signaling pathway.2024Cell death & disease免费全文
  74. TNKS1BP1 facilitates ubiquitination of CNOT4 by TRIM21 to promote hepatocellular carcinoma progression and immune evasion.2024Cell death & disease免费全文
  75. HMGB1 promotes mitochondrial transfer between hepatocellular carcinoma cells through RHOT1 and RAC1 under hypoxia.2024Cell death & disease免费全文
  76. Bifidobacterium longum promotes postoperative liver function recovery in patients with hepatocellular carcinoma.2024Cell host & microbe
  77. The switch triggering the invasion process: Lipid metabolism in the metastasis of hepatocellular carcinoma.2024Chinese medical journal免费全文
  78. SP1-activated USP27X-AS1 promotes hepatocellular carcinoma progression via USP7-mediated AKT stabilisation.2024Clinical and translational medicine免费全文
  79. Liquid-liquid phase separation-related lncRNA prognostic signature and ZNF32-AS2 as a novel biomarker in hepatocellular carcinoma.2024Computers in biology and medicine
  80. A Randomized Comparison of Transradial and Transfemoral Approach in Hepatic Arterial Infusion Chemotherapy.2024Current medical imagingRCT
  81. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma.2024Drug discovery today
  82. Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma.2024EBioMedicine免费全文
  83. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.2024Frontiers in immunology免费全文
  84. Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma.2024Frontiers in immunology免费全文
  85. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.2024Gastroenterology
  86. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.2024Gut免费全文
  87. Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity.2024Hepatology international
  88. The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma.2024Immunology
  89. SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy.2024International immunopharmacology
  90. SLC41A1 overexpression correlates with immune cell infiltration in HCC and promotes its malignant progression.2024International journal of medical sciences免费全文
  91. The Prognostic and Therapeutic Roles of ARL-6 Gene in Hepatocellular Carcinoma.2024International journal of medical sciences免费全文
  92. Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9.2024International journal of oncology免费全文
  93. Contradictory Role of Gadd45β in Liver Diseases.2024Journal of cellular and molecular medicine免费全文
  94. Postoperative lenvatinib + PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with microvascular invasion (Barcelona Clinic Liver Cancer stage 0 or A): a propensity score matching analysis.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  95. N6-methyladenosine modification of circular RNA circASH2L suppresses growth and metastasis in hepatocellular carcinoma through regulating hsa-miR-525-3p/MTUS2 axis.2024Journal of translational medicine免费全文
  96. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.2024La Radiologia medica
  97. Improvements in advanced hepatocellular carcinoma to repeat implementation of primary protocol after cancer progression occurs following sequential systemic therapy and a clinical trial: A case report.2024Medicine免费全文
  98. USP26 as a hepatitis B virus-induced deubiquitinase primes hepatocellular carcinogenesis by epigenetic remodeling.2024Nature communications免费全文
  99. Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention.2024Pathogens (Basel, Switzerland)免费全文
  100. NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma.2024Scientific reports免费全文
  101. Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.2024Surgical endoscopy
  102. Preclinical evaluation of radiolabeled tissue factor-targeted peptide for theranostics of hepatocellular carcinoma post percutaneous ethanol injection.2024Theranostics免费全文
  103. Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment.2024Trends in endocrinology and metabolism: TEM
  104. Comparison of Sonazoid-Contrast‑Enhanced Ultrasound and Gd‑EOB‑DTPA‑Enhanced MRI for Predicting Microvascular Invasion in Hepatocellular Carcinoma.2024Ultrasound in medicine & biology
  105. Is ALPPS still appropriate for large or locally advanced hepatocellular carcinoma in an era of targeted agents and immunotherapy?2024Updates in surgery
  106. Core-shell cisplatin/SiO2 nanocapsules combined with PTC-209 overcome chemotherapy-Acquired and intrinsic resistance in hepatocellular carcinoma.2023Acta biomaterialia
  107. Bone Lesion-Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5-Targeting miR-3190-5p.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  108. A Prospective Study Using Propensity Score Matching to Compare Long-term Survival Outcomes After Robotic-assisted, Laparoscopic, or Open Liver Resection for Patients With BCLC Stage 0-A Hepatocellular Carcinoma.2023Annals of surgery
  109. Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.2023BMC cancer免费全文
  110. MicroRNA-188-5p inhibits hepatocellular carcinoma proliferation and migration by targeting forkhead box N2.2023BMC cancer免费全文
  111. Identification and in vitro and in vivo validation of the key role of GSDME in pyroptosis-related genes signature in hepatocellular carcinoma.2023BMC cancer免费全文
  112. CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors.2023Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  113. Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy.2023Cancer letters
  114. Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression.2023Cell death and differentiation免费全文
  115. The role of pyroptosis in hepatocellular carcinoma.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  116. LINC01980 induced by TGF-beta promotes hepatocellular carcinoma metastasis via miR-376b-5p/E2F5 axis.2023Cellular signalling
  117. TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: Case report.2023Clinics and research in hepatology and gastroenterology
  118. Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect.2023Critical reviews in oncology/hematology
  119. Scientific Hepatectomy for Hepatocellular Carcinoma.2023Current medical science
  120. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.2023Current medical science
  121. Prognostic Factors of Liver Transplantation for Hepatocellular Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis.2023Current medical science
  122. Long noncoding RNA MAPKAPK5-AS1 promotes metastasis through regulation miR-376b-5p/ECT2 axis in hepatocellular carcinoma.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  123. A nomogram for preoperative prediction of microvascular invasion in ruptured hepatocellular carcinoma.2023European journal of gastroenterology & hepatology
  124. Repeat hepatectomy versus microwave ablation for solitary and small (≤3 cm) recurrent hepatocellular carcinoma with early or late recurrence: A propensity score matched study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  125. Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: What's the impact?2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  126. Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: A propensity score matching analysis.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  127. HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response.2023European radiology
  128. Identifying the programmed cell death index of hepatocellular carcinoma for prognosis and therapy response improvement by machine learning: a bioinformatics analysis and experimental validation.2023Frontiers in immunology免费全文
  129. Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody fol2023Frontiers in immunology免费全文
  130. Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies.2023Frontiers in immunology免费全文
  131. Identification of molecular pattern and prognostic risk model based on ligand-receptor pairs in liver cancer.2023Frontiers in immunology免费全文
  132. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors.2023Frontiers in immunology免费全文
  133. Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review.2023Frontiers in immunology免费全文
  134. Alkaline phosphatase combined with γ-glutamyl transferase is an independent predictor of prognosis of hepatocellular carcinoma patients receiving programmed death-1 inhibitors.2023Frontiers in immunology免费全文
  135. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.2023Frontiers in immunology免费全文
  136. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.2023Genetics research免费全文
  137. Des-gamma-carboxy prothrombin is a promising biomarker of hepatocellular carcinoma and a predictor of complications in patients with chronic liver diseases.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  138. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.2023Hepatology (Baltimore, Md.)免费全文
  139. Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression.2023Hepatology (Baltimore, Md.)免费全文
  140. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.2023International immunopharmacology
  141. CENPA functions as a transcriptional regulator to promote hepatocellular carcinoma progression via cooperating with YY1.2023International journal of biological sciences免费全文
  142. Comprehensive Analysis of Sideroflexin 4 in Hepatocellular Carcinoma by Bioinformatics and Experiments.2023International journal of medical sciences免费全文
  143. Histone H3 activates caspase-1 and promotes proliferation and metastasis in hepatocellular carcinoma.2023International journal of medical sciences免费全文
  144. Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis.2023Journal of cancer research and clinical oncology免费全文
  145. Prognostic value of preoperative circulating tumor cells for hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score analysis.2023Journal of cancer research and clinical oncology免费全文
  146. Risk Factors of Positive Resection Margin in Hepatectomy for Resectable Ruptured Hepatocellular Carcinoma: Risk Prediction and Prognosis.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  147. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.2023Journal of hematology & oncology免费全文
  148. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.2023Journal of hepatology
  149. The stromal-tumor amplifying STC1-Notch1 feedforward signal promotes the stemness of hepatocellular carcinoma.2023Journal of translational medicine免费全文
  150. LINC01608 activated by YY1 facilitate hepatocellular carcinoma progression by modulating the EGFR/ERK axis.2023Liver international : official journal of the International Association for the Study of the Liver
  151. Intelectin-1 is a novel prognostic biomarker for hepatocellular carcinoma.2023Medicine免费全文
  152. MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma.2023Oncogene
  153. A micropeptide JunBP regulated by TGF-β promotes hepatocellular carcinoma metastasis.2023Oncogene免费全文
  154. Diagnostic Value of OPNI in Hepatocellular Carcinoma.2023Oncology
  155. The correlation between tumor-associated macrophages and the prognosis of east Asian hepatocellular carcinoma patients: A systematic review and meta-analysis.2023Pathology, research and practice
  156. Targeting super enhancers for liver disease: a review.2023PeerJ免费全文
  157. METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.2023Scientific reports免费全文
  158. Dynamic contrast-enhanced ultrasonography with sonazoid predicts microvascular invasion in early-stage hepatocellular carcinoma.2023The British journal of radiology免费全文
  159. MYC-activated LINC00607 promotes hepatocellular carcinoma progression by regulating the miR-584-3p/ROCK1 axis.2023The journal of gene medicine
  160. Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma.2022Aging免费全文
  161. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.2022BMC gastroenterology免费全文
  162. The effect of the number of hepatic inflow occlusion times on the prognosis of ruptured hepatocellular carcinoma patients after hepatectomy.2022BMC surgery免费全文
  163. Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  164. Tumor-associated macrophages in liver cancer: From mechanisms to therapy.2022Cancer communications (London, England)免费全文
  165. HNRNPC downregulation inhibits IL-6/STAT3-mediated HCC metastasis by decreasing HIF1A expression.2022Cancer science免费全文
  166. Cell adhesion molecule BVES functions as a suppressor of tumor cells extrusion in hepatocellular carcinoma metastasis.2022Cell communication and signaling : CCS免费全文
  167. ALKBH5-mediated m6A modification of lincRNA LINC02551 enhances the stability of DDX24 to promote hepatocellular carcinoma growth and metastasis.2022Cell death & disease免费全文
  168. USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling.2022Cell death & disease免费全文
  169. Non-coding small nucleolar RNA SNORD17 promotes the progression of hepatocellular carcinoma through a positive feedback loop upon p53 inactivation.2022Cell death and differentiation免费全文
  170. Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma.2022Cells免费全文
  171. Hsa-microRNA-27b-3p inhibits hepatocellular carcinoma progression by inactivating transforming growth factor-activated kinase-binding protein 3/nuclear factor kappa B signalling.2022Cellular & molecular biology letters免费全文
  172. Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.2022Cellular oncology (Dordrecht, Netherlands)免费全文
  173. Protein arginine methyltransferase 3 promotes glycolysis and hepatocellular carcinoma growth by enhancing arginine methylation of lactate dehydrogenase A.2022Clinical and translational medicine免费全文
  174. Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.2022Current medical imaging
  175. Changes in Inflammatory Markers Predict the Prognosis of Resected Hepatocellular Carcinoma with Child-Pugh A.2022Current oncology (Toronto, Ont.)免费全文
  176. Alpha-Fetoprotein+Alkaline Phosphatase (A-A) Score Can Predict the Prognosis of Patients with Ruptured Hepatocellular Carcinoma Underwent Hepatectomy.2022Disease markers免费全文
  177. Hepatectomy for ruptured hepatocellular carcinoma classified as Barcelona Clinic Liver Cancer stage 0/A: The optimal treatment.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  178. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.2022European radiology
  179. Identifying potential pharmacological targets and mechanisms of vitamin D for hepatocellular carcinoma and COVID-19.2022Frontiers in immunology免费全文
  180. Case report: Mycobacterium neoaurum infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis.2022Frontiers in immunology免费全文
  181. A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses.2022Frontiers in immunology免费全文
  182. Bone metastasis of hepatocellular carcinoma: facts and hopes from clinical and translational perspectives.2022Frontiers of medicine
  183. Pan-cancer analysis combined with experimental validation revealed IL4I1 as an immunological and prognostic biomarker.2022International immunopharmacology
  184. Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma.2022International journal of cancer
  185. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.2022Irish journal of medical science
  186. TRIM proteins in hepatocellular carcinoma.2022Journal of biomedical science免费全文
  187. HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET.2022Journal of experimental & clinical cancer research : CR免费全文
  188. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway.2022Journal of experimental & clinical cancer research : CR免费全文
  189. T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1.2022Oncogene
  190. DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4 to ARF6.2022Oncogene免费全文
  191. DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevity免费全文
  192. Comparison of the prognosis of BCLC stage A ruptured hepatocellular carcinoma patients after undergoing transarterial chemoembolization (TACE) or hepatectomy: a propensity score-matched landmark analysis.2022Surgical endoscopy
  193. 18[Formula: see text]-Glycyrrhetinic Acid Inhibits TGF-[Formula: see text]-Induced Epithelial-to-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Targeting STAT3.2022The American journal of Chinese medicine
  194. Overexpression of BACH1 mediated by IGF2 facilitates hepatocellular carcinoma growth and metastasis via IGF1R and PTK2.2022Theranostics免费全文
  195. Postoperative outcomes and recurrence patterns of intermediate-stage hepatocellular carcinoma dictated by the sum of tumor size and number.2022World journal of gastroenterology免费全文
  196. Ultrasound-based artificial intelligence in gastroenterology and hepatology.2022World journal of gastroenterology免费全文
  197. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.2021Abdominal radiology (New York)
  198. Oxygen-Challenge Blood Oxygen Level-Dependent Magnetic Resonance Imaging for Evaluation of Early Change of Hepatocellular Carcinoma to Chemoembolization: A Feasibility Study.2021Academic radiology
  199. Downregulation of lncRNA SBF2-AS1 inhibits hepatocellular carcinoma proliferation and migration by regulating the miR-361-5p/TGF-β1 signaling pathway.2021Aging免费全文
  200. Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma.2021Aging免费全文
  201. SnoRD126 promotes the proliferation of hepatocellular carcinoma cells through transcriptional regulation of FGFR2 activation in combination with hnRNPK.2021Aging免费全文
  202. Combined identification of ARID1A, CSMD1, and SENP3 as effective prognostic biomarkers for hepatocellular carcinoma.2021Aging免费全文
  203. Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.2021Aging免费全文
  204. Comment on "Sub-classification of Microscopic Vascular Invasion in Hepatocellular Carcinoma".2021Annals of surgery
  205. ASO Author Reflections: Collagen Contents of Liver Tissue Are Significantly Correlated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Hepatocellular Carcinoma Patients with Child-Pugh Grade A Liver Function.2021Annals of surgical oncology
  206. Liver Collagen Contents Are Closely Associated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma and Child-Pugh Grade A Liver Function.2021Annals of surgical oncology
  207. TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27.2021BioMed research international免费全文
  208. LncRNA influence sequential steps of hepatocellular carcinoma metastasis.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  209. LncRNA NBR2 inhibits tumorigenesis by regulating autophagy in hepatocellular carcinoma.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  210. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.2021Cancer medicine免费全文
  211. Diagnostic value of gamma-glutamyl transpeptidase to alkaline phosphatase ratio combined with gamma-glutamyl transpeptidase to aspartate aminotransferase ratio and alanine aminotransferase to aspartate aminotransferase ratio in alpha-fetopr2021Cancer medicine免费全文
  212. ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY.2021Cell death & disease免费全文
  213. Circular RNA circUBE2J2 acts as the sponge of microRNA-370-5P to suppress hepatocellular carcinoma progression.2021Cell death & disease免费全文
  214. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells.2021Cell death & disease免费全文
  215. GRAMD4 inhibits tumour metastasis by recruiting the E3 ligase ITCH to target TAK1 for degradation in hepatocellular carcinoma.2021Clinical and translational medicine免费全文
  216. L-EGCG-Mn nanoparticles as a pH-sensitive MRI contrast agent.2021Drug delivery免费全文
  217. ESR1 mediated circ_0004018 suppresses angiogenesis in hepatocellular carcinoma via recruiting FUS and stabilizing TIMP2 expression.2021Experimental cell research
  218. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway.2021Experimental cell research
  219. Exploring the Prognostic Value, Immune Implication and Biological Function of H2AFY Gene in Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  220. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  221. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.2021Frontiers of medicine
  222. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.2021Hepatology (Baltimore, Md.)
  223. H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p.2021Hepatology (Baltimore, Md.)
  224. HRC promotes anoikis resistance and metastasis by suppressing endoplasmic reticulum stress in hepatocellular carcinoma.2021International journal of medical sciences免费全文
  225. Comprehensive analysis of partial epithelial mesenchymal transition-related genes in hepatocellular carcinoma.2021Journal of cellular and molecular medicine免费全文
  226. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.2021Journal of experimental & clinical cancer research : CR免费全文
  227. Long non-coding RNA CCDC183-AS1 acts AS a miR-589-5p sponge to promote the progression of hepatocellular carcinoma through regulating SKP1 expression.2021Journal of experimental & clinical cancer research : CR免费全文
  228. FOXC1 promotes HCC proliferation and metastasis by Upregulating DNMT3B to induce DNA Hypermethylation of CTH promoter.2021Journal of experimental & clinical cancer research : CR免费全文
  229. Long noncoding RNA SNHG14 promotes hepatocellular carcinoma progression by regulating miR-876-5p/SSR2 axis.2021Journal of experimental & clinical cancer research : CR免费全文
  230. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.2021Journal of hepatology免费全文
  231. Identification of MCM family as potential therapeutic and prognostic targets for hepatocellular carcinoma based on bioinformatics and experiments.2021Life sciences
  232. Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis.2021Molecular medicine reports免费全文
  233. Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy.2021Scientific reports免费全文
  234. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.2021Theranostics免费全文
  235. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.2021Theranostics免费全文
  236. Acute graft-versus-host disease after liver transplantation in a close contact with COVID-19: A case report.2021Transplant immunology免费全文
  237. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.2021Ultrasound in medicine & biology
  238. Author's Reply: Use of Direct Liver Stiffness Measurement in Evaluating the Severity of Liver Cirrhosis in Patients with Hepatocellular Carcinoma.2021World journal of surgery
中文论文(未计入)1
  1. [Immunotherapy clinical application and research prospects for liver cancer].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)73
  1. AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation即将招募NCT07732504牵头方不分期2026-10 启动
  2. Denosumab Strategy for Liver Cancer With Bone Metastases即将招募NCT07537972牵头方II期2026-05 启动
  3. Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases即将招募NCT07537959牵头方不分期2026-04 启动
  4. Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma正在招募NCT07413354牵头方II期2026-04 启动
  5. AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma即将招募NCT07729618牵头方不分期2026-10 启动
  6. Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer即将招募NCT07537946牵头方III期2026-05 启动
  7. Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC即将招募NCT07350824牵头方不分期2025-12 启动
  8. Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention正在招募NCT07282184牵头方I/II期2025-10 启动
  9. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension即将招募NCT07350070牵头方II期2025-12 启动
  10. Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study即将招募NCT07064668牵头方II期2025-07 启动
  11. Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence正在招募NCT06954116牵头方II期2025-08 启动
  12. AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)正在招募NCT07062380牵头方2025-06 启动
  13. Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion即将招募NCT06089369牵头方III期2024-06 启动
  14. Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance正在招募NCT06653062牵头方2024-11 启动
  15. Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer正在招募NCT07838415牵头方2024-10 启动
  16. HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma正在招募NCT06187961牵头方II期2023-12 启动
  17. Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing正在招募NCT05520788牵头方2020-05 启动
  18. A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence进行中,不再招募NCT07009470牵头方不分期2025-02 启动
  19. Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma已完成NCT07030842牵头方2023-08 启动
  20. A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection状态不明NCT06089382牵头方III期2023-11 启动
  21. Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma状态不明NCT05717738牵头方2022-01 启动
  22. Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma进行中,不再招募NCT07444905牵头方2022-02 启动
  23. PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer状态不明NCT05103007牵头方不分期2021-12 启动
  24. Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC状态不明NCT05420922牵头方2021-11 启动
  25. Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma已完成NCT05178524牵头方不分期2021-06 启动
  26. Primary Hepatobiliary Cancer Cohort of Central China状态不明NCT05520801牵头方2020-05 启动
  27. The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study已完成NCT07639294牵头方2018-06 启动
  28. The Effect of Gut Microbiota on Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma已完成NCT04303286牵头方2018-10 启动
  29. Circulating Tumor Cell Detection in Hepatocellular Carcinoma已完成NCT05297955牵头方2013-11 启动
  30. Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma即将招募NCT06896396牵头方(推断)I/II期2025-04 启动
  31. Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma正在招募NCT07154082牵头方(推断)II期2025-12 启动
  32. QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma即将招募NCT06822985牵头方(推断)I期2025-02 启动
  33. Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension正在招募NCT06280313牵头方(推断)2024-03 启动
  34. Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma正在招募NCT06470256牵头方(推断)I期2024-06 启动
  35. Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma正在招募NCT06311929牵头方(推断)IV期2024-04 启动
  36. A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC状态不明NCT05839197牵头方(推断)II期2023-05 启动
  37. Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC状态不明NCT05533892牵头方(推断)I期2022-09 启动
  38. Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma已完成NCT06776185牵头方(推断)2022-01 启动
  39. Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation已完成NCT06248554牵头方(推断)不分期2021-01 启动
  40. Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma状态不明NCT05031949牵头方(推断)I期2021-10 启动
  41. ML Models for Predicting Postoperative Peritoneal Metastasis After Hepatocellular Carcinoma Rupture已完成NCT06102278牵头方(推断)2020-01 启动
  42. Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma状态不明NCT04076631牵头方(推断)2019-08 启动
  43. Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma状态不明NCT03881501牵头方(推断)2019-03 启动
  44. Postoperative Adjuvant Therapy of HCC Based on PD-1已完成NCT05307926牵头方(推断)2019-02 启动
  45. Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC状态不明NCT06461936牵头方(推断)2019-01 启动
  46. Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling已完成NCT06298123牵头方(推断)2019-02 启动
  47. Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.进行中,不再招募NCT06248528牵头方(推断)不分期2019-12 启动
  48. Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma状态不明NCT03652896牵头方(推断)不分期2019-01 启动
  49. A Long-term Survival Analysis of Different Surgical Method in Early Hepatocellular Carcinoma已完成NCT05117047牵头方(推断)2015-02 启动
  50. Infrahepatic Inferior Vena Cava Clamping Versus Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping状态不明NCT02405416牵头方(推断)不分期2015-03 启动
  51. Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy状态不明NCT02319863牵头方(推断)不分期1994-02 启动
  52. cfDNA Methylation for Liver Cancer Recurrence Detection正在招募NCT07466602研究中心2025-09 启动
  53. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  54. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  55. Phase 2 Study of WGI-0301 for Advanced HCC正在招募NCT06309485研究中心II期2024-07 启动
  56. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  57. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection正在招募NCT06560827研究中心I期2023-10 启动
  58. A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients邀请入组NCT05441475研究中心II期2021-12 启动
  59. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  60. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer已撤回NCT05292443研究中心2021-12 启动
  61. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  62. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  63. Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC状态不明NCT04241523研究中心II期2020-01 启动
  64. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  65. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  66. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  67. Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma状态不明NCT04227808研究中心II期2019-12 启动
  68. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  69. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  70. the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma已完成NCT01717066研究中心不分期2012-11 启动
  71. Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy已终止NCT01760616研究中心IV期2011-11 启动
  72. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy已完成NCT01770431研究中心IV期2011-08 启动
  73. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)已完成NCT00617981研究中心III期2008-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 45 篇,占 0.5%。

牵头论文
45
2021–2025 年
牵头试验
15
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
8
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 4420222023: 111120232024: 101020242025: 10102025

武汉有 5 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 12

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
    分期
    未注明
    开始
    2025-07
    登记号
    NCT07078136

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  2. 正在招募
    Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
    分期
    不分期
    开始
    2024-03
    登记号
    NCT06597227

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  3. 正在招募
    Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
    分期
    II期
    开始
    2023-11
    登记号
    NCT06199895

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  4. 正在招募
    Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
    分期
    未注明
    开始
    2023-08
    登记号
    NCT06413212

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  5. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  6. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  7. 正在招募
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    分期
    不分期
    开始
    2024-09
    登记号
    NCT06128252

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 11 家列出的医院为研究中心上海、乌鲁木齐、南京、武汉、沈阳、西安、重庆

  8. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  9. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

  10. 正在招募
    Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
    分期
    II期
    开始
    2023-03
    登记号
    NCT05687357

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南京鼓楼医院;另有 2 家列出的医院为研究中心南京、太原、武汉

  11. 正在招募
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2023-04
    登记号
    NCT05918094

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 7 家列出的医院为研究中心上海、南昌、哈尔滨、大连、广州、成都、武汉、郑州

  12. 即将招募
    A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
    分期
    II期
    开始
    2025-11
    登记号
    NCT07233850

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术影像与人工智能化疗与综合治疗
论文中的科室肿瘤内科消化/肝病科影像/核医学科病理/检验科
牵头的论文45
  1. Cancer cell-extrinsic STING shapes immune-active microenvironment and predicts clinical outcome in gastric cancer.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Effects of Thymidine Phosphorylase and Sine Oculis Homeobox Homologue 1 on the Prognosis and Immune Microenvironment of Gastric Cancer.2025Current medical science
  3. Exploring the effect of capsaicin on gene expression and chemotherapy sensitization in gastric cancer cells.2025European journal of medical research免费全文
  4. The circRNA circSCAF8 promotes tumor growth and metastasis of gastric cancer via miR-1293/TIMP1signaling.2025Gene therapy
  5. Unveiling lymphocyte dynamics: Navigating postoperative immune landscapes in gastric cancer patients undergoing laparoscopic D2 gastrectomy.2025International journal of immunopathology and pharmacology免费全文
  6. Prospective multicenter validation of a machine learning model for predicting anastomotic leakage in patients with gastric adenocarcinoma undergoing total or proximal gastrectomy.2025International journal of surgery (London, England)免费全文
  7. Survival benefit from adjuvant chemoradiotherapy in local advanced gastric cancer without accurate D2 confirmation: a real-world retrospective study (TJ-ARK01).2025PeerJ免费全文
  8. Machine learning-based prediction of duodenal stump leakage following laparoscopic gastrectomy for gastric cancer.2025Surgery
  9. Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.2025The oncologistRCT免费全文
  10. Prophylactic antibiotic use is associated with better clinical outcomes in gastric cancer patients receiving immunotherapy.2025The oncologist免费全文
  11. A Novel Nomogram to Predict Resectable Gastric Cancer Based on Preoperative Circulating Tumor Cell.2024Clinical and translational gastroenterology免费全文
  12. Amino acid metabolism-related genes as potential biomarkers and the role of MATN3 in stomach adenocarcinoma: A bioinformatics, mendelian randomization and experimental validation study.2024International immunopharmacology
  13. Role of AT-rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives.2024Journal of cellular and molecular medicine免费全文
  14. Identification of histopathological classification and establishment of prognostic indicators of gastric adenocarcinoma based on deep learning algorithm.2024Medical molecular morphology免费全文
  15. OCTA-based research on changes of retinal microcirculation in digestive tract malignancy.2024Photodiagnosis and photodynamic therapy
  16. Sensitivity and specificity of folate receptor α-positive circulating tumour cells in gastric cancer.2024Postgraduate medical journal
  17. The number of mesogastria containing metastatic lymph nodes predicts gastric cancer prognosis.2024SurgeryRCT
  18. Author response to: Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).2024The British journal of surgery
  19. Author response to: Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).2024The British journal of surgery
  20. Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).2024The British journal of surgeryRCT
  21. PWSC: a novel clustering method based on polynomial weight-adjusted sparse clustering for sparse biomedical data and its application in cancer subtyping.2023BMC bioinformatics免费全文
  22. The role of lncRNA SNHG14 in gastric cancer: enhancing tumor cell proliferation and migration, and mechanisms of CDH2 expression.2023Cell cycle (Georgetown, Tex.)免费全文
  23. Determination of an Appropriate Endoscopic Monitoring Interval for Patients with Gastric Precancerous Conditions in China.2023Current medical science
  24. Bacterial infection and microbiota in carcinogenesis and tumor development.2023Frontiers in cellular and infection microbiology免费全文
  25. Revalidation of the ATTRACTION-4 study in a real-world setting: a multicenter, retrospective propensity score matching study in China.2023Frontiers in immunology免费全文
  26. Short-term prognostic role of peripheral lymphocyte subsets in patients with gastric cancer.2023International immunopharmacology
  27. MKL-1 suppresses ferroptosis by activating system Xc- and increasing glutathione synthesis.2023International journal of biological sciences免费全文
  28. Relationship between endoscopic gastric abnormalities and colorectal polyps: a cross-sectional study based on 33439 Chinese patients.2023International journal of medical sciences免费全文
  29. Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer.2023Oncology research and treatment
  30. Collagen type V alpha 2 promotes the development of gastric cancer via M2 macrophage polarization.2023The Chinese journal of physiology
  31. Prospective Comparison of Oral Contrast-Enhanced Transabdominal Ultrasound Imaging With Contrast-Enhanced Computed Tomography in Pre-operative Tumor Staging of Gastric Cancer.2023Ultrasound in medicine & biology
  32. Combination of berberine and low glucose inhibits gastric cancer through the PP2A/GSK3β/MCL-1 signaling pathway.2022European journal of pharmacology
  33. Epstein-Barr Virus is Associated with Gastric Cancer Precursor: Atrophic Gastritis.2022International journal of medical sciences免费全文
  34. Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China.2022Scandinavian journal of gastroenterology
  35. Short-term outcomes of D2 lymphadenectomy plus complete mesogastric excision for gastric cancer: a propensity score matching analysis.2022Surgical endoscopy
  36. Clinico-pathologic determinants of non-e-curative outcome following en-bloc endoscopic submucosal dissection in patients with early gastric neoplasia.2021BMC cancer免费全文
  37. Bioinformatics analysis identifies COL1A1, THBS2 and SPP1 as potential predictors of patient prognosis and immunotherapy response in gastric cancer.2021Bioscience reports免费全文
  38. Complete mesogastric excision for locally advanced gastric cancer: short-term outcomes of a randomized clinical trial.2021Cell reports. MedicineRCT免费全文
  39. Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.2021Current medical science
  40. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  41. Bibliometric Evaluation of Publications (2000-2020) on the Prognosis of Gastric Cancer.2021Inquiry : a journal of medical care organization, provision and financing免费全文
  42. PARP inhibitors in gastric cancer: beacon of hope.2021Journal of experimental & clinical cancer research : CR免费全文
  43. Gastrin-17 induces gastric cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.2021Journal of physiology and biochemistry
  44. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.2021Pathology oncology research : POR免费全文
  45. Intussusception after reconstruction following gastrectomy for gastric cancer.2021World journal of surgical oncology免费全文
中文论文(未计入)6
  1. [The impact of neoadjuvant immunotherapy on postoperative complications and short-term efficacy in patients with advanced gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Immunotherapy: progress and challenges of a revolutionary treatment for gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Attach importance to functional evaluation after gastric-preserving surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Rethinking the scope of lymphadenectomy after neoadjuvant immunotherapy for locally advanced gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Development of membrane anatomy theory in gastric cancer surgery].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Demonstration and significance on proximal segment of dorsal mesogastrium].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)40
  1. Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis正在招募NCT07078136牵头方(推断)2025-07 启动
  2. Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy正在招募NCT06597227牵头方(推断)不分期2024-03 启动
  3. Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer正在招募NCT06199895牵头方(推断)II期2023-11 启动
  4. Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing正在招募NCT06413212牵头方(推断)2023-08 启动
  5. Effect of Gastrectomy on Gut Microbiome and Cognitive Function状态不明NCT06186089牵头方(推断)2024-01 启动
  6. Comparison of pCLE and EB in Gastric Lesion Diagnosis状态不明NCT06389448牵头方(推断)不分期2024-04 启动
  7. The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer状态不明NCT06592287牵头方(推断)I/II期2024-09 启动
  8. Validation of a Model for Predicting Anastomotic Leakage已完成NCT05646290牵头方(推断)2022-01 启动
  9. Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer已终止NCT04294784牵头方(推断)II期2020-04 启动
  10. The Number of Mesogastria Containing Metastatic Lymph Nodes Predicts Gastric Cancer Prognosis已完成NCT06697821牵头方(推断)2020-05 启动
  11. Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma状态不明NCT03801668牵头方(推断)III期2019-03 启动
  12. Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer状态不明NCT03601988牵头方(推断)III期2018-07 启动
  13. Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision(D2+CME)for Advanced Gastric Cancer状态不明NCT01978444牵头方(推断)不分期2014-09 启动
  14. The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study状态不明NCT02583659牵头方(推断)2013-01 启动
  15. Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer状态不明NCT01197118牵头方(推断)II期2010-09 启动
  16. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  17. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  18. A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers即将招募NCT07233850研究中心II期2025-11 启动
  19. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  20. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer正在招募NCT06128252研究中心不分期2024-09 启动
  21. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  22. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT05918094研究中心III期2023-04 启动
  23. Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma正在招募NCT05687357研究中心II期2023-03 启动
  24. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)进行中,不再招募NCT06710132研究中心I/II期2025-01 启动
  25. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China已完成NCT06585501研究中心2024-08 启动
  26. Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis已完成NCT06109805研究中心2023-10 启动
  27. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  28. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  29. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  30. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  31. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  32. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  33. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  34. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  35. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer已完成NCT04053205研究中心I/II期2019-11 启动
  36. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma已完成NCT03469557研究中心II期2017-07 启动
  37. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  38. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  39. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  40. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 5 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

武汉有 16 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

武汉有 2 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
牵头的论文1
  1. Competing risk nomogram for predicting prognosis of patients with spinal and pelvic chordoma: A SEER-based retrospective study.2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.5%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 3320232024: 2220242025: 002025

武汉有 22 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文12
  1. Construction and clinical validation of a machine-learning-based consensus prognostic signature (MLPS) for osteosarcoma via multi-cohort data integration.2026International immunopharmacology
  2. OTULIN confers cisplatin resistance in osteosarcoma by mediating GPX4 protein homeostasis to evade the mitochondrial apoptotic pathway.2024Journal of experimental & clinical cancer research : CR
  3. EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy.2024Journal of nanobiotechnology
  4. Cancer-Erythrocyte Membrane-Mimicking Fe3O4 Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors.2023ACS applied materials & interfaces
  5. Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis.2023Journal of orthopaedic surgery and research
  6. P2RX7 promotes osteosarcoma progression and glucose metabolism by enhancing c-Myc stabilization.2023Journal of translational medicine
  7. Predictive value of preoperative platelet-to-albumin ratio and apolipoprotein B-to-apolipoprotein A1 ratio for osteosarcoma in children and adolescents: a retrospective study of 118 cases.2022BMC cancer
  8. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.2022EBioMedicine
  9. Infiltration of LPAR5+ macrophages in osteosarcoma tumor microenvironment predicts better outcomes.2022Frontiers in immunology
  10. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.2022Journal of surgical oncology
  11. TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation.2021Cell death & disease
  12. Comprehensive Analysis of Key mRNAs and lncRNAs in Osteosarcoma Response to Preoperative Chemotherapy with Prognostic Values.2021Current medical science
早期论文(2016–2020 年)14
  1. Specific Small-Molecule NIR-II Fluorescence Imaging of Osteosarcoma and Lung Metastasis.2020Advanced healthcare materials
  2. Key genes with prognostic values in suppression of osteosarcoma metastasis using comprehensive analysis.2020BMC cancer
  3. HOTAIR Promotes Cisplatin Resistance of Osteosarcoma Cells by Regulating Cell Proliferation, Invasion, and Apoptosis via miR-106a-5p/STAT3 Axis.2020Cell transplantation
  4. Expression of CXCR4 and MMP-2 is associated with poor prognosis in patients with osteosarcoma.2020Histology and histopathology
  5. Knockdown of STIP1 inhibits the invasion of CD133‑positive cancer stem‑like cells of the osteosarcoma MG63 cell line via the PI3K/Akt and ERK1/2 pathways.2020International journal of molecular medicine
  6. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.2019International journal of cancer
  7. Survival analysis of patients with metastatic osteosarcoma: a Surveillance, Epidemiology, and End Results population-based study.2019International orthopaedics
  8. Integrative analyses of key genes and regulatory elements in fluoride-affected osteosarcoma.2019Journal of cellular biochemistry
  9. Matrix stiffness regulates epithelial-mesenchymal transition via cytoskeletal remodeling and MRTF-A translocation in osteosarcoma cells.2019Journal of the mechanical behavior of biomedical materials
  10. Clinical Features and Long-Term Outcome of Primary Intracranial Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumors: 14 Cases From a Single Institution.2019World neurosurgery
  11. Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma.2018Cell death & disease
  12. MMP-1 Over-expression Promotes Malignancy and Stem-Like Properties of Human Osteosarcoma MG-63 Cells In Vitro.2018Current medical science
  13. Flavonoids Active Against Osteosarcoma: A Review of the Molecular Mechanisms Involved.2017Current pharmaceutical design
  14. Meningeal Ewing Sarcoma/Peripheral PNET: Clinicopathological, Immunohistochemical and FISH study of four cases.2017Neuropathology : official journal of the Japanese Society of Neuropathology

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

武汉有 9 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
    分期
    未注明
    开始
    2025-07
    登记号
    NCT07078136

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文3
  1. MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression.2023Current medical science
  2. Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China.2022Scandinavian journal of gastroenterology
  3. Current knowledge of primary prostatic extra-gastrointestinal stromal tumor: a case report and review of the literature.2021The Journal of international medical research
早期论文(2016–2020 年)8
  1. Assessment of tumor heterogeneity: Differentiation of periampullary neoplasms based on CT whole-lesion histogram analysis.2019European journal of radiology
  2. Tumor heterogeneity in gastrointestinal stromal tumors of the small bowel: volumetric CT texture analysis as a potential biomarker for risk stratification.2018Cancer imaging : the official publication of the International Cancer Imaging Society
  3. miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT.2018Cell communication and signaling : CCS
  4. Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling.2018Molecular cancer
  5. CD117 is not always positive in infantile gastrointestinal stromal tumor.2018World journal of pediatrics : WJP
  6. Imbedding pancreaticojejunostomy used in pure laparoscopic pancreaticoduodenectomy for nondilated pancreatic duct.2017Surgical endoscopy
  7. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.2016Oncotarget
  8. [Comparison of the clinical efficacy of laparoscopic wedge resection and open wedge resection for the treatment of gastrointestinal stromal tumor].2016Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis正在招募NCT07078136牵头方(推断)2025-07 启动
  2. CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study即将招募NCT07106411牵头方(推断)2025-08 启动
  3. A Real-world Comparison of FNB and FNA in IHC-required Lesions.已完成NCT05565066牵头方(推断)2014-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.7%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 1120242025: 552025

武汉有 10 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05701306

    年龄 5 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心天津、广州、武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科影像/核医学科神经内科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Integrated bulk and single-cell RNA sequencing reveals a cuproptosis-related LncRNA prognostic signature in neuroblastoma.2025BMC cancer
  2. Identification of Crucial Genes Associated With MYCN-Driven Neuroblastoma Based on Single-Cell Analysis and Machine Learning.2025Cancer medicine
  3. Distal-less homeobox 5 transactivated by MYCN contributes to progression of neuroblastoma through AKT signaling pathway.2025Cellular signalling
  4. Leveraging small voxel with optimal acquisition time for [18F]mFBG total-body PET/CT imaging in pediatric patients with neuroblastoma: a preliminary study.2025European journal of nuclear medicine and molecular imaging
  5. Prediction of neuroblastoma prognosis with a novel T-cell exhaustion-related gene signature.2025Scientific reports
  6. MicroRNA-218-5p-Ddx41 axis restrains microglia-mediated neuroinflammation through downregulating type I interferon response in a mouse model of Parkinson's disease.2024Journal of translational medicine
  7. NTRK1-mediated protection against manganese-induced neurotoxicity and cell apoptosis via IGF2 in SH-SY5Y cells.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. Transcriptomics reveals the effects of NTRK1 on endoplasmic reticulum stress response-associated genes in human neuronal cell lines.2023PeerJ
早期论文(2016–2020 年)5
  1. Identification of prognostic long noncoding RNAs associated with spontaneous regression of neuroblastoma.2020Cancer medicine
  2. NBPF1 independently determine the risk stratification and prognosis of patients with neuroblastoma.2020Genomics
  3. Combined analysis of RNA-sequence and microarray data reveals effective metabolism-based prognostic signature for neuroblastoma.2020Journal of cellular and molecular medicine
  4. Analytical validation and clinical application of urinary vanillylmandelic acid and homovanillic acid by LC-MS/MS for diagnosis of neuroblastoma.2019Biomedical chromatography : BMC
  5. Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.2017Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors正在招募NCT05701306研究中心I/II期2023-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 6 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 19 篇,占 1.1%。

牵头论文
19
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
12
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 3320222023: 4420232024: 2220242025: 442025

武汉有 3 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 15

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
    分期
    早期I期
    开始
    2025-01
    登记号
    NCT06791681

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  2. 正在招募
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
    分期
    I期
    开始
    2022-03
    登记号
    NCT05219721

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  3. 即将招募
    A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
    分期
    不分期
    开始
    2026-02
    登记号
    NCT07376720

    年龄 18 岁 至 78 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  4. 正在招募
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-02
    登记号
    NCT07258511

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安

  5. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  6. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  7. 正在招募
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07555938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛

  8. 正在招募
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    分期
    未注明
    开始
    2026-06
    登记号
    NCT07663253

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 9 家列出的医院为研究中心上海、北京、南宁、南通、广州、成都、昆明、武汉、西安、郑州

  9. 正在招募
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06083207

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、南京、南宁、天津、徐州、武汉、苏州、西安

  10. 正在招募
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    分期
    未注明
    开始
    2024-12
    登记号
    NCT07028970

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、武汉、郑州

  11. 正在招募
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    分期
    III期
    开始
    2022-09
    登记号
    NCT05243797

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春

  12. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  13. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  14. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

  15. 即将招募
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    分期
    早期I期
    开始
    2026-01
    登记号
    NCT07399444

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 4 家列出的医院为研究中心南昌、天津、徐州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题CAR-T 与细胞治疗复发与耐药联合用药
论文中的科室神经内科
牵头的论文19
  1. Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma.2025Cancer medicine免费全文
  2. A successful haploidentical transplantation without conditioning regimen for a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy.2025Cytotherapy
  3. Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma.2025Journal of translational medicine免费全文
  4. Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma.2025Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  5. B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis.2024EMBO molecular medicine免费全文
  6. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy.2024Proceedings of the National Academy of Sciences of the United States of America免费全文
  7. The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.2023BMC cancer免费全文
  8. A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma.2023Journal of translational medicine免费全文
  9. Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndrome: A case report and literature review.2023Medicine免费全文
  10. Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma.2023Thrombosis research
  11. Rare Distribution of Sclerotic Bony Lesions in Multiple Myeloma: A Case Report.2022Clinical nuclear medicine
  12. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.2022Journal for immunotherapy of cancer免费全文
  13. Refractory postherpetic neuralgia in a multiple myeloma patient with lenalidomide maintenance therapy: a case report.2022The Journal of international medical research免费全文
  14. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.2021Blood
  15. Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy.2021Blood cancer journal免费全文
  16. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.2021Clinical and translational medicine免费全文
  17. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.2021Current medical science
  18. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.2021Frontiers in immunology免费全文
  19. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.2021Medicine免费全文
中文论文(未计入)1
  1. [Correlation analysis of polyclonal plasma cell proportion in the bone marrow with clinical characteristics of patients with newly diagnosed multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)30
  1. A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment即将招募NCT07376720牵头方(推断)不分期2026-02 启动
  2. A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma正在招募NCT06791681牵头方(推断)早期I期2025-01 启动
  3. A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia正在招募NCT05219721牵头方(推断)I期2022-03 启动
  4. A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma状态不明NCT05201118牵头方(推断)I期2022-01 启动
  5. Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#状态不明NCT05266768牵头方(推断)I期2022-04 启动
  6. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma正在招募NCT07555938研究中心III期2026-06 启动
  7. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  8. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients正在招募NCT07663253研究中心2026-06 启动
  9. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07258511研究中心III期2026-02 启动
  10. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)即将招募NCT07399444研究中心早期I期2026-01 启动
  11. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  12. Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection正在招募NCT07028970研究中心2024-12 启动
  13. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma正在招募NCT06083207研究中心I/II期2024-07 启动
  14. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  15. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation正在招募NCT05243797研究中心III期2022-09 启动
  16. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  17. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  18. A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06934044研究中心I期2025-05 启动
  19. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  20. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  21. Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies状态不明NCT05672420研究中心I/II期2023-01 启动
  22. the Safety and Efficacy of SENL103 Autologous T Cell Injection状态不明NCT06067581研究中心早期I期2023-08 启动
  23. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  24. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  25. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma已终止NCT04735575研究中心I/II期2021-05 启动
  26. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)状态不明NCT05066646研究中心I/II期2020-04 启动
  27. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)已完成NCT03748953研究中心III期2019-01 启动
  28. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  29. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  30. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy已完成NCT02609828研究中心III期2015-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 7 篇,占 3.1%。

牵头论文
7
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 1120242025: 332025

武汉有 3 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    分期
    不分期
    开始
    2025-01
    登记号
    NCT06689917

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  2. 正在招募
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-01
    登记号
    NCT06764238

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛

  3. 正在招募
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06882057

    年龄 1 岁 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛

  4. 正在招募
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    分期
    III期
    开始
    2025-03
    登记号
    NCT07152041

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 20 家列出的医院为研究中心上海、南京、南昌、天津、广州、成都、武汉、济南、深圳、福州、苏州、贵阳、重庆、长沙、青岛

  5. 正在招募
    A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
    分期
    I期
    开始
    2024-09
    登记号
    NCT06927466

    年龄 3 岁 至 25 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、南昌、徐州、武汉、苏州

  6. 正在招募
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    分期
    II期
    开始
    2022-01
    登记号
    NCT05334823

    年龄 3 岁 至 21 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、苏州、郑州、重庆、长沙

  7. 正在招募
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    分期
    I/II期
    开始
    2022-11
    登记号
    NCT05579132

    年龄 2 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心天津、广州、徐州、成都、杭州、武汉、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题儿童CAR-T 与细胞治疗抗体与靶向药物
论文中的科室肿瘤内科儿科
牵头的论文7
  1. Blinatumomab in pediatric B-acute lymphoblastic leukemia.2025Frontiers in immunology免费全文
  2. Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.2025Journal of translational medicine免费全文
  3. FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.2025Leukemia & lymphoma
  4. Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.2024Cancer medicine免费全文
  5. MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy.2023Cancer immunology, immunotherapy : CII免费全文
  6. Functional diversification and dynamics of CAR-T cells in patients with B-ALL.2023Cell reports
  7. Upregulation of CD22 by Chidamide promotes CAR T cells functionality.2021Scientific reports免费全文
中文论文(未计入)1
  1. [Research progress on copy number alterations in pediatric B-cell acute lymphoblastic leukemia].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia正在招募NCT06689917牵头方不分期2025-01 启动
  2. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol正在招募NCT06764238研究中心II/III期2025-01 启动
  3. Newly-diagnosed Pediatric Ph-positive B-ALL Protocol正在招募NCT07152041研究中心III期2025-03 启动
  4. Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol正在招募NCT06882057研究中心II/III期2025-03 启动
  5. A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.正在招募NCT06927466研究中心I期2024-09 启动
  6. A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents正在招募NCT05334823研究中心II期2022-01 启动
  7. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)正在招募NCT05579132研究中心I/II期2022-11 启动
  8. Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL状态不明NCT04888442研究中心I期2020-10 启动
  9. Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents已完成NCT04888468研究中心I期2019-11 启动
  10. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)已完成NCT03476239研究中心III期2017-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 8 篇,占 1.9%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 1120232024: 1120242025: 332025

武汉有 4 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
    分期
    不分期
    开始
    2026-05
    登记号
    NCT07552506

    年龄 14 岁 至 50 岁;仅女性(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院;另有 3 家列出的医院为研究中心杭州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植免疫抑制治疗促血小板生成药物
牵头的论文8
  1. Alemtuzumab for haematological malignancies.2025Annals of hematology免费全文
  2. Parvovirus B19-induced aplastic anemia following mechanical valve replacement.2025The Journal of international medical research免费全文
  3. Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.2025Transplantation and cellular therapy
  4. Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide.2024Transplantation and cellular therapy
  5. An atypical patient with bone marrow failure syndrome-2 without microcephaly and learning disability in a Chinese family.2023British journal of haematology
  6. Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?2022Transplantation and cellular therapy
  7. Comparisons of Modified Post-Transplantation Cyclophosphamide and Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin Regimens for Haploidentical Stem Cell Transplantation in Patients with Aplastic Anemia.2022Transplantation and cellular therapy
  8. Haploidentical Transplantation with Modified Post-transplantation Cyclophosphamide for Patients with Primary Aplastic Anemia: A Multicenter Experience.2021Transplantation and cellular therapy
中文论文(未计入)1
  1. [Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria].2021Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin即将招募NCT07552506研究中心不分期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 20 篇,占 5.0%。

牵头论文
20
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 5520232024: 1120242025: 662025

武汉有 2 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
    分期
    未注明
    开始
    2019-07
    登记号
    NCT03491605

    年龄未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题EB病毒与感染诱因诊断与预后遗传与家族性
论文中的科室病理/检验科风湿免疫科
牵头的论文20
  1. A case of cirrhosis concurrent with NK/T-Cell lymphoma and hemophagocytic lymphohistiocytosis: a clinical report and literature review.2025BMC infectious diseases免费全文
  2. The lncRNA LINC02446 promotes tumor progression and HLH occurrence by regulating the expression of KLRs and IL-10 in EBV-NK-LPDs.2025International immunopharmacology
  3. UNC13D c.2588G>A Nucleotide Variant Impairs NK-Cell Cytotoxicity in Adult-Onset EBV-Associated Hemophagocytic Lymphohistiocytosis: A Pedigree Study.2025International journal of molecular sciences免费全文
  4. Unveiling fatal risk factors: Predicting hemophagocytic lymphohistiocytosis in SFTS patients.2025PLoS neglected tropical diseases免费全文
  5. Deep insight into cytokine storm: from pathogenesis to treatment.2025Signal transduction and targeted therapy免费全文
  6. Immune profiling and prognosis implications in severe fever with thrombocytopenia syndrome with and without hemophagocytic lymphohistiocytosis.2025Travel medicine and infectious disease
  7. Comprehensive evaluation of immune dysregulation in secondary hemophagocytic lymphohistiocytosis.2024Virulence免费全文
  8. IFN-α induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review.2023Frontiers in immunology免费全文
  9. The signature and predictive value of immune parameters in patients with secondary hemophagocytic lymphohistiocytosis.2023Immunobiology
  10. Hemophagocytic lymphohistiocytosis with a hemizygous PRF1 c.674G>A mutation.2023The American journal of the medical sciences
  11. Clinical and genetic characterization of Epstein-Barr virus-associated T/NK-cell lymphoproliferative diseases.2023The Journal of allergy and clinical immunology
  12. Clinical profile, etiology, and outcome of hemophagocytic lymphohistiocytosis associated with histiocytic necrotizing lymphadenitis.2023World journal of pediatrics : WJP免费全文
  13. The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases.2022Hematological oncology
  14. Tuberculosis infection related hemophagocytic lymphohistiocytosis diagnosed in patient with GZMB mutation: A case report and literature review.2022Medicine免费全文
  15. Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis.2022The Journal of allergy and clinical immunology免费全文
  16. Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis.2021Annals of hematology
  17. Clinical and genetic features of Epstein-Barr virus-triggered late-onset primary hemophagocytic lymphohistiocytosis: Ten pedigrees study.2021Clinical and translational medicine免费全文
  18. Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study.2021Clinical lymphoma, myeloma & leukemia
  19. Infection-associated Hemophagocytic Syndrome in Critically Ill Patients with COVID-19.2021Current medical science免费全文
  20. Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms.2021European journal of human genetics : EJHG免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection正在招募NCT03491605牵头方(推断)2019-07 启动
PubMed 以外找到的论文(未计入)6
  1. Dendritic cell–based vaccines (KSD-101) against EBV-associated lymphoproliferative diseases: Results from an ongoing phase I clinical study.2025Journal of Clinical Oncology论文
  2. Humanized anti-CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults: A prospective, open-label clinical trial2025Blood会议摘要
  3. CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.2024Journal of Clinical Oncology会议摘要
  4. Clinical analysis of seven cases of hemophagocytic lymphohistiocytosis secondary to cutaneous T-cell lymphoma2023Chinese Journal of Dermatology论文
  5. Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study2023Blood会议摘要
  6. Outcomes of PD-1 Inhibitors Treatment of Chronic Active Epstein Barr Virus Infection : A Single Center Retrospective Analysis2022Blood论文

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 3 家医院列在β 地中海贫血下全国有 133 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Alpha and beta-Thalassemia mutations in Hubei area of China.2020BMC medical genetics

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 4 篇,占 1.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 2220242025: 002025

武汉有 2 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
    分期
    III期
    开始
    2022-12
    登记号
    NCT05611801

    年龄 1 岁 至 17 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、天津、武汉

  2. 正在招募
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    分期
    III期
    开始
    2021-11
    登记号
    NCT05145127

    年龄 1 岁 至 74 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、广州、武汉、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科肿瘤内科病理/检验科
牵头的论文4
  1. Investigation and Analysis of the Current Status of Health-Related Quality of Life in Adolescents with Hemophilia in Hubei Province.2024British journal of hospital medicine (London, England : 2005)
  2. Clinical Analysis and Mental Health Survey of Hemophilia Carriers: a Cross-sectional Study.2024Current medical science
  3. An aberrant F8 intron 1 inversion with concomitant large duplication and deletion in a Chinese severe hemophilia A patient.2021Hematology (Amsterdam, Netherlands)
  4. TWIN BROTHERS WITH VARIABLE PHENOTYPES OF HAEMOPHILIA A RESULTING FROM MATERNAL MOSAICISM OF ARG550CYS OF F8.2021Journal of paediatrics and child health
中文论文(未计入)1
  1. [Analysis of a patient with severe Hemophilia A due to a large duplication of F8 gene].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
早期论文(2016–2020 年)8
  1. Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China.2020Haemophilia : the official journal of the World Federation of Hemophilia
  2. Clinical findings in a patient with haemophilia A affected by COVID-19.2020Haemophilia : the official journal of the World Federation of Hemophilia
  3. Determining the cutoff value of the APTT mixing test for factor VIII inhibitor.2019Clinical chemistry and laboratory medicine
  4. F8 IVS9+5G>A mutation causes moderate haemophilia A.2019Haemophilia : the official journal of the World Federation of Hemophilia
  5. A Retrospective Analysis of Intracranial Hemorrhage in Children with Hemophilia A.2018Current medical science
  6. Performance of next-generation sequencing in the detection of large exon deletion in patients of haemophilia A.2018Haemophilia : the official journal of the World Federation of Hemophilia
  7. Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.2017Medicine
  8. [Study of gene mutation in 62 hemophilia A children].2017Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B正在招募NCT05611801研究中心III期2022-12 启动
  2. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors正在招募NCT05145127研究中心III期2021-11 启动
  3. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A即将招募NCT06136507研究中心III期2026-12 启动
  4. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A已完成NCT05707351研究中心III期2023-03 启动
  5. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A进行中,不再招募NCT05685238研究中心III期2023-02 启动
  6. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors已完成NCT05053139研究中心III期2021-12 启动
  7. A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ,Fc Fusion Protein for Injection已完成NCT05251090研究中心I期2021-06 启动
  8. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A已完成NCT02492984研究中心IV期2015-04 启动
  9. Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A已完成NCT02634723研究中心2015-12 启动
  10. China ADVATE PTP Study已完成NCT02170402研究中心IV期2014-06 启动
  11. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)已完成NCT02078427研究中心2011-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 6 篇,占 9.4%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025

武汉有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室病理/检验科消化/肝病科
牵头的论文6
  1. Improving the PLASMIC score with the use of RDW-SD in the differential diagnosis for thrombotic thrombocytopenic purpura in Chinese patients.2026Annals of clinical biochemistry
  2. Prognostic value of laboratory biomarkers for mortality risk stratification in thrombotic thrombocytopenic purpura.2025Annals of hematology
  3. A Novel Variant on the Thrombospondin Type-1 Repeat 2 Domain of ADAMTS13 in a Parturient with Suspected Hereditary Thrombotic Thrombocytopenic Purpura and Unusually High ADAMTS13 Activity.2024Seminars in thrombosis and hemostasis
  4. Identification of 8 Rare Deleterious Variants in ADAMTS13 by Next-generation Sequencing in a Chinese Population with Thrombotic Thrombocytopenic Purpura.2023Current medical science
  5. A Case of Parturient with Hereditary Thrombotic Thrombocytopenic Purpura: Case Report of a Novel Variant.2022Seminars in thrombosis and hemostasis
  6. Thrombotic thrombocytopenic purpura complicated with acute aortic dissection: A case report.2021Medicine
中文论文(未计入)1
  1. [Advance in the diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
早期论文(2016–2020 年)2
  1. [N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura: a case report].2020Zhonghua nei ke za zhi
  2. Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients.2018Thrombosis research
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura进行中,不再招募NCT04683003研究中心III期2021-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 18 篇,占 3.7%。

牵头论文
18
2021–2025 年
牵头试验
7
任何状态,ClinicalTrials.gov
牵头的开放试验
7
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 6620232024: 4420242025: 112025

武汉有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
    分期
    I期
    开始
    2026-04
    登记号
    NCT07526493

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  2. 正在招募
    The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
    分期
    I期
    开始
    2025-03
    登记号
    NCT06620809

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  3. 正在招募
    Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
    分期
    未注明
    开始
    2025-07
    登记号
    NCT06885957

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  4. 正在招募
    Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
    分期
    不分期
    开始
    2024-08
    登记号
    NCT06474520

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  5. 正在招募
    Biomarkers in Autoimmune Disease of Nervous System
    分期
    未注明
    开始
    2024-07
    登记号
    NCT06502015

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  6. 正在招募
    Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
    分期
    早期I期
    开始
    2020-09
    登记号
    NCT04561557

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  7. 即将招募
    Tongji NADs Cohort
    分期
    未注明
    开始
    2026-03
    登记号
    NCT07333196

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  8. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断影像急性发作治疗
论文中的科室神经内科影像/核医学科
牵头的论文18
  1. Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.2025Neurology
  2. Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.2024Brain : a journal of neurology
  3. Segmental abnormalities of white matter microstructure in multiple sclerosis and neuromyelitis optica spectrum disorder identified by automated fiber quantification.2024Multiple sclerosis and related disorders
  4. Serum LDL Promotes Microglial Activation and Exacerbates Demyelinating Injury in Neuromyelitis Optica Spectrum Disorder.2024Neuroscience bulletin免费全文
  5. Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity.2024Science immunology
  6. Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model.2023Annals of neurology
  7. Research hotspots and trends on neuromyelitis optica spectrum disorders: insights from bibliometric analysis.2023Frontiers in immunology免费全文
  8. Editorial: Immune Mechanisms in white matter lesions: Clinical and pathophysiological implications.2023Frontiers in immunology免费全文
  9. TREM2 deficiency inhibits microglial activation and aggravates demyelinating injury in neuromyelitis optica spectrum disorder.2023Journal of neuroinflammation免费全文
  10. Structural covariance in subcortical regions in multiple sclerosis and neuromyelitis optica spectrum disorders: An MRI-based study with automated brain volumetry.2023Multiple sclerosis and related disorders
  11. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.2023Signal transduction and targeted therapy免费全文
  12. Fractional anisotropy helps to differentiate the optic nerve impairment between neuromyelitis optica spectrum disorders and multiple sclerosis.2022European radiology
  13. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG+ NMOSD mimicking intracranial infection as the initial manifestation.2022Multiple sclerosis and related disorders
  14. Distinct Immunological Features of Inflammatory Demyelinating Diseases of the Central Nervous System.2022Neuroimmunomodulation
  15. Case Report: Clinical and Imaging Characteristics of a Patient with Anti-flotillin Autoantibodies: Neuromyelitis Optica or Multiple Sclerosis?2021Frontiers in immunology免费全文
  16. Dynamic Changes in AQP4-IgG Level and Immunological Markers During Protein-A Immunoadsorption Therapy for NMOSD: A Case Report and Literature Review.2021Frontiers in immunology免费全文
  17. Regulatory T cells protect against brain damage by alleviating inflammatory response in neuromyelitis optica spectrum disorder.2021Journal of neuroinflammation免费全文
  18. Modified models to distinguish central nervous system demyelinating diseases with brain lesions.2021Multiple sclerosis and related disorders
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Tongji NADs Cohort即将招募NCT07333196牵头方2026-03 启动
  2. Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.正在招募NCT07526493牵头方I期2026-04 启动
  3. Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD正在招募NCT06885957牵头方2025-07 启动
  4. The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders正在招募NCT06620809牵头方I期2025-03 启动
  5. Biomarkers in Autoimmune Disease of Nervous System正在招募NCT06502015牵头方2024-07 启动
  6. Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)正在招募NCT06474520牵头方不分期2024-08 启动
  7. Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System正在招募NCT04561557牵头方早期I期2020-09 启动
  8. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动
  9. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders进行中,不再招募NCT06044350研究中心II期2023-08 启动
PubMed 以外找到的论文(未计入)3
  1. A Real-World Study of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder (P11-8.012)2025Neurology论文
  2. Anti-BCMA CAR T-CELL therapy CT103A in relapsed or refractory AQP4-IGG seropositive neuromyelitis optica spectrum disorders: Phase 1 trial interim results2023Journal of the Neurological Sciences论文
  3. Contribution of clinical attacks to the irreversible disability in NMOSD (S50.007)2023Neurology论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 4.5%。

牵头论文
11
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 6620222023: 1120232024: 0020242025: 332025

武汉有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
    分期
    早期I期
    开始
    2024-07
    登记号
    NCT06497361

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  2. 正在招募
    Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
    分期
    早期I期
    开始
    2024-07
    登记号
    NCT06497387

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  3. 正在招募
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    分期
    I/II期
    开始
    2026-01
    登记号
    NCT07061938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、成都、武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断与鉴别治疗与复发头颈、眼眶与唾液腺
论文中的科室风湿免疫科影像/核医学科
牵头的论文11
  1. Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study.2025Annals of the rheumatic diseasesRCT
  2. Omics in IgG4-related disease.2025Chinese medical journal免费全文
  3. Serum N-Glycan Signatures as Potential Biomarkers for the Detection and Monitoring of IgG4-Related Disease.2025Journal of proteome research
  4. BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.2023Annals of the rheumatic diseases免费全文
  5. Clinical value of 18F-FDG PET/CT in IgG4-related disease.2022Annals of nuclear medicine
  6. Update on classification, diagnosis, and management of immunoglobulin G4-related disease.2022Chinese medical journal免费全文
  7. Role of eosinophilia in IgG4-related disease.2022Clinical and experimental rheumatology
  8. Multi-System Langerhans Cell Histiocytosis as a Mimic of IgG4-Related Disease: A Case Report and Literature Review.2022Frontiers in endocrinology免费全文
  9. Proteomic characteristics of saliva in patients with different subgroups of IgG4-RD.2022Frontiers in immunology免费全文
  10. Potential roles of non-lymphocytic cells in the pathogenesis of IgG4-related disease.2022Frontiers in immunology免费全文
  11. IgG4-Related Disease: A Retrospective Chinese Study of Features and Treatment Response of 98 Patients Including 4 Rare Cases.2021Current medical science
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease正在招募NCT06497387牵头方早期I期2024-07 启动
  2. Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease正在招募NCT06497361牵头方早期I期2024-07 启动
  3. the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases进行中,不再招募NCT07339540牵头方早期I期2025-11 启动
  4. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease正在招募NCT07061938研究中心I/II期2026-01 启动
  5. A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease进行中,不再招募NCT05662241研究中心III期2023-01 启动
PubMed 以外找到的论文(未计入)4
  1. Potential roles of antibodies with different classes in IgG4‐related diseases2025Rheumatology & autoimmunity论文
  2. Case Report: A Rare Manifestation of IgG4 ‐Related Disease: Isolated Hepatocellular Injury2024International Journal of Rheumatic Diseases论文
  3. POS0347 INSIGHTS INTO THE DESIGN AND STUDY POPULATION OF MITIGATE: THE FIRST MULTINATIONAL RANDOMIZED CONTROLLED CLINICAL TRIAL IN IgG4 RELATED DISEASE (IgG4-RD), EVALUATING THE EFFICACY AND SAFETY OF INEBILIZUMAB2024Annals of the Rheumatic Diseases会议摘要
  4. IgG4-Related Disease2023Springer eBooks书籍章节

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 17 篇,占 3.4%。

牵头论文
17
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
8
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 5520232024: 4420242025: 442025

武汉有 3 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
    分期
    I期
    开始
    2026-04
    登记号
    NCT07526493

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  2. 正在招募
    GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
    分期
    早期I期
    开始
    2025-07
    登记号
    NCT07058298

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  3. 正在招募
    CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
    分期
    早期I期
    开始
    2025-12
    登记号
    NCT07337785

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  4. 正在招募
    Biomarkers in Autoimmune Disease of Nervous System
    分期
    未注明
    开始
    2024-07
    登记号
    NCT06502015

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  5. 正在招募
    Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
    分期
    早期I期
    开始
    2020-09
    登记号
    NCT04561557

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  6. 即将招募
    Tongji NADs Cohort
    分期
    未注明
    开始
    2026-03
    登记号
    NCT07333196

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  7. 即将招募
    Universal STAR-T Cell Injection in Generalized Myasthenia Gravis
    分期
    I期
    开始
    2026-07
    登记号
    NCT07714798

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  8. 即将招募
    A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
    分期
    早期I期
    开始
    2026-12
    登记号
    NCT07917923

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

  9. 正在招募
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    分期
    III期
    开始
    2024-06
    登记号
    NCT06463587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题常规免疫治疗胸腺与胸腺切除抗体与诊断
论文中的科室神经内科
牵头的论文17
  1. Perioperative Efgartigimod treatment for acute myasthenia gravis exacerbation with retroperitoneal mass: a case report.2025BMC neurology免费全文
  2. The real-world impact of corticosteroid-associated adverse events in myasthenia gravis: A patient-reported survey analysis.2025Cellular immunology
  3. The JAK1/3 Inhibitor Tofacitinib Regulates Th Cell Profiles and Humoral Immune Responses in Myasthenia Gravis.2025Muscle & nerve
  4. Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  5. Type B thymomas in patients with myasthenia gravis display a distinctive pattern of αβ TCR and IL-7 receptor α expression on CD4+CD8+ thymocytes.2024Autoimmunity
  6. B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis.2024EMBO molecular medicine免费全文
  7. Exhausted signature and regulatory network of NK cells in myasthenia gravis.2024Frontiers in immunology免费全文
  8. Effect of thymectomy on the frequencies of peripheral regulatory B and T lymphocytes in patients with Myasthenia gravis-a pilot study.2024The International journal of neuroscience
  9. Development and validation of the scale for symptom clusters in patients with myasthenia gravis.2023BMC neurology免费全文
  10. Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.2023Frontiers in immunology免费全文
  11. Effects of symptom clusters on quality of life mediated by self-efficacy among individuals with myasthenia gravis: A structural equation modelling analysis.2023Journal of clinical nursing
  12. Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology免费全文
  13. Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.2023Pediatric neurology
  14. Childhood-Onset Myasthenia Gravis Patients Benefited from Thymectomy in a Long-Term Follow-up Observation.2022European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie免费全文
  15. Subxiphoid-subcostal thoracoscopic thymectomy for seropositive myasthenia offers equivalent remission rates and potentially faster recovery.2022Interactive cardiovascular and thoracic surgery免费全文
  16. Differences in immunophenotypes between myasthenia gravis patients with and without thyroid antibodies.2022Muscle & nerve
  17. Upregulation of circ-FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR-133/PAX7.2021Cell biology international免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. Tongji NADs Cohort即将招募NCT07333196牵头方2026-03 启动
  2. Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.正在招募NCT07526493牵头方I期2026-04 启动
  3. CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases正在招募NCT07337785牵头方早期I期2025-12 启动
  4. Biomarkers in Autoimmune Disease of Nervous System正在招募NCT06502015牵头方2024-07 启动
  5. Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System正在招募NCT04561557牵头方早期I期2020-09 启动
  6. Universal STAR-T Cell Injection in Generalized Myasthenia Gravis即将招募NCT07714798牵头方(推断)I期2026-07 启动
  7. A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis即将招募NCT07917923牵头方(推断)早期I期2026-12 启动
  8. GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)正在招募NCT07058298牵头方(推断)早期I期2025-07 启动
  9. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)正在招募NCT06463587研究中心III期2024-06 启动
  10. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis进行中,不再招募NCT06298552研究中心III期2024-04 启动
  11. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis进行中,不再招募NCT06558279研究中心III期2024-09 启动
  12. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动
  13. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis已终止NCT04963270研究中心III期2021-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

武汉有 3 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Treatment of Moyamoya Disease With iPSC-derived Exosomes
    分期
    I期
    开始
    2025-05
    登记号
    NCT07065409

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与脑血流中风与出血
论文中的科室神经外科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

胆道闭锁

Biliary atresia

2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

武汉有 2 家医院列在胆道闭锁下全国有 31 家医院列在胆道闭锁下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Nutritional Intervention for Biliary Atresia
    分期
    不分期
    开始
    2025-02
    登记号
    NCT06764082

    年龄 1 天 至 3 个月(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题Kasai手术长期结局发病机制
论文中的科室儿科
牵头的论文2
  1. Efficacy of sodium bicarbonate Ringer's solution for perioperative fluid management in infants with biliary atresia: a prospective multicenter study.2025Pediatric surgery international
  2. Mechanism of biliary atresia caused by T follicular helper cells-induced immune injury.2024BMC pediatrics免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Nutritional Intervention for Biliary Atresia正在招募NCT06764082牵头方不分期2025-02 启动
  2. Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy已完成NCT04370145牵头方IV期2021-05 启动
PubMed 以外找到的论文(未计入)2
  1. Liver transplantation2024Elsevier eBooks书籍章节
  2. Pregnancy after organ transplantation2024Elsevier eBooks书籍章节

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

武汉有 5 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 14 篇,占 1.4%。

牵头论文
14
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 3320232024: 4420242025: 332025

武汉有 9 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文14
  1. Associations between dietary patterns and the incidence of idiopathic pulmonary fibrosis: A cohort study.2026The journal of nutrition, health & aging
  2. Semaphorin 3E-Plexin D1 Axis Drives Lung Fibrosis through ErbB2-Mediated Fibroblast Activation.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. Targeting PBK in the fibroblast-to-myofibroblast transition: A novel therapeutic strategy for IPF.2025Biochemical pharmacology
  4. Six1 promotes alveolar epithelium senescence in pulmonary fibrosis through regulating Tp53.2025International immunopharmacology
  5. Alpinetin ameliorates bleomycin-induced pulmonary fibrosis by repressing fibroblast differentiation and proliferation.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. Localized Administration of Bcar3 siRNA via Nano-Self-Assembly to Treat Idiopathic Pulmonary Fibrosis by Disrupting Macrophage-Fibroblast Crosstalk.2024International journal of nanomedicine
  7. Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [18F]ATX-1905.2024Molecular pharmaceutics
  8. Regulation of myofibroblast dedifferentiation in pulmonary fibrosis.2024Respiratory research
  9. Lung Transplantation: A Viable Option for Connective Tissue Disease?2023Arthritis care & research
  10. Genetic Programs Between Steroid-Sensitive and Steroid-Insensitive Interstitial Lung Disease.2023Inflammation
  11. The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis.2023Medicina (Kaunas, Lithuania)
  12. The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.2022The European respiratory journal
  13. A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese.2021Journal of clinical laboratory analysis
  14. Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis.2021Theranostics
早期论文(2016–2020 年)10
  1. Indirubin alleviates bleomycin-induced pulmonary fibrosis in mice by suppressing fibroblast to myofibroblast differentiation.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. Response.2020Chest
  3. Response.2020Chest
  4. Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis.2020Chest
  5. Blocking protein phosphatase 2A with a peptide protects mice against bleomycin-induced pulmonary fibrosis.2020Experimental lung research
  6. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.2020Oncoimmunology
  7. Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-β-induced fibroblast to myofibroblast differentiation.2020Respiratory research
  8. Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis.2019Cell death & disease
  9. Targeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis.2018Human mutation
  10. Macrophages: friend or foe in idiopathic pulmonary fibrosis?2018Respiratory research
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  2. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06335303研究中心II期2024-09 启动
  3. A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects已完成NCT05895565研究中心I期2023-05 启动
  4. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05321069研究中心III期2022-10 启动
  5. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  6. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04594707研究中心III期2021-08 启动
  7. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT04419558研究中心III期2020-09 启动
  8. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT03955146研究中心III期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 1 篇,占 2.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

武汉有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 27 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 11 篇,占 1.4%。

牵头论文
11
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 1120232024: 3320242025: 442025

武汉有 6 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
    分期
    早期I期
    开始
    2025-01
    登记号
    NCT06849609

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科影像/核医学科
牵头的论文11
  1. Cd16-Cd56bright NK Cells: A Protective NK Cell Subset for Progression and Prognosis in Amyotrophic Lateral Sclerosis.2025Aging and disease
  2. White matter integrity mediated the effect of plasma uric acid levels on cognitive function in ALS patients.2025Brain imaging and behavior
  3. Association between cardiac autonomic dysfunction, cognitive impairment, and survival in patients with amyotrophic lateral sclerosis.2025Clinical autonomic research : official journal of the Clinical Autonomic Research Society
  4. Astrocytes Contribute to Motor Neuron Degeneration in ALS via the TRAIL-DR5 Signaling Pathway.2025Journal of neurochemistry
  5. Association between apathy and caregiver burden in patients with amyotrophic lateral sclerosis: a cross-sectional study.2024BMJ open
  6. Quantitative MRI Analysis of Brachial Plexus and Limb-Girdle Muscles in Upper Extremity Onset Amyotrophic Lateral Sclerosis.2024Journal of magnetic resonance imaging : JMRI
  7. Brain-derived neurotrophic factor/tropomyosin receptor kinase B signaling in spinal muscular atrophy and amyotrophic lateral sclerosis.2024Neurobiology of disease
  8. The level of homocysteine in amyotrophic lateral sclerosis: a systematic review and meta-analysis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review.2022Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  10. Decreased blood CD4+ T lymphocyte helps predict cognitive impairment in patients with amyotrophic lateral sclerosis.2021BMC neurology
  11. The illness experience for people with amyotrophic lateral sclerosis: A qualitative study.2021Journal of clinical nursing
早期论文(2016–2020 年)3
  1. Region-specific atrophy of precentral gyrus in patients with amyotrophic lateral sclerosis.2018Journal of magnetic resonance imaging : JMRI
  2. Modeling hallmark pathology using motor neurons derived from the family and sporadic amyotrophic lateral sclerosis patient-specific iPS cells.2018Stem cell research & therapy
  3. Sporadic ALS Astrocytes Induce Neuronal Degeneration In Vivo.2017Stem cell reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS正在招募NCT06849609牵头方(推断)早期I期2025-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 3 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

武汉有 3 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文2
  1. Identifying inversions with breakpoints in the Dystrophin gene through long-read sequencing: report of two cases.2024BMC medical genomics
  2. Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function.2021FASEB journal : official publication of the Federation of American Societies for Experimental Biology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

武汉有 7 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

武汉有 3 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 21 篇,占 2.9%。

牵头论文
21
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 3320232024: 2220242025: 882025

武汉有 8 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科儿科影像/核医学科
牵头的论文21
  1. Prognosis and predictive factors in pediatric IgA nephropathy.2026Pediatric nephrology (Berlin, Germany)
  2. Identifying the potential therapeutic targets of tertiary lymphoid structure in IgA nephropathy based on bioinformatics.2025Autoimmunity
  3. Pathogenic synonymous variation of the COL4A3 gene causing Alport syndrome comorbid with IgA deposition in a toddler: a case report.2025BMC nephrology
  4. Network Pharmacological Analysis of Hydroxychloroquine Intervention in the Treatment of Iga Nephropathy.2025Current pharmaceutical design
  5. Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study.2025Drug design, development and therapy
  6. Efficacy and Long-Term Outcomes of Tacrolimus versus Cyclophosphamide and Mycophenolate Mofetil in the Management of Pediatric IgA Vasculitis Nephritis: A Cohort Study in Single-Center.2025Drug design, development and therapy
  7. Development and Validation of a Predictive Model for Severe Tubular Atrophy/Interstitial Fibrosis in Patients with IgA Nephropathy: Multicenter Retrospective Study.2025JMIR medical informatics
  8. Exploring the Relationship Between 91 Inflammatory Cytokines and IgA Nephropathy Using a Two-Sample Mendelian Randomization Study and the Gene Expression Omnibus Database.2025Mediators of inflammation
  9. Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study.2025Pediatric rheumatology online journal
  10. Circulating soluble CD30 is associated with renal tertiary lymphoid structures and the progression of IgA nephropathy.2024Clinica chimica acta; international journal of clinical chemistry
  11. Exploring the causal effect of complement and IgA nephropathy-a Mendelian randomization study.2024Renal failure
  12. High Renal Mast Cell Density Is Associated with Poor Prognosis in Patients with Immunoglobulin A Nephropathy.2023American journal of nephrology
  13. T Follicular Helper Cells in Tertiary Lymphoid Structure Contribute to Renal Fibrosis by IL-21.2023International journal of molecular sciences
  14. Noninvasive Assessment of the Renal Function, Oxford Classification and Prognostic Risk Stratification of IgAN by Using Intravoxel Incoherent Motion Diffusion-Weighted Imaging and Blood Oxygenation Level-Dependent MRI.2023Journal of magnetic resonance imaging : JMRI
  15. Shrunken Pore Syndrome Is Associated with Renal Function Decline in Female Patients with Kidney Diseases.2022BioMed research international
  16. Clinical and Pathological Implications of Increases in Tonsillar CD19+CD5+ B Cells, CD208+ Dendritic Cells, and IgA1-positive Cells of Immunoglobulin A Nephropathy.2022Current medical science
  17. CD137L-macrophage induce lymphatic endothelial cells autophagy to promote lymphangiogenesis in renal fibrosis.2022International journal of biological sciences
  18. Interleukin-7 Is Associated with Clinical and Pathological Activities in Immunoglobulin A Nephropathy and Protects the Renal Proximal Tubule Epithelium from Cellular Fibrosis.2021Current medical science
  19. Severe glomerular C3 deposition indicates severe renal lesions and a poor prognosis in patients with immunoglobulin A nephropathy.2021Histopathology
  20. The prognostic value of platelet-to-lymphocyte ratio on the long-term renal survival in patients with IgA nephropathy.2021International urology and nephrology
  21. Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A.2021Theranostics
中文论文(未计入)1
  1. [Prognosis and risk factors of IgA vasculitis nephritis in children].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
早期论文(2016–2020 年)6
  1. Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: a case report.2020BMC nephrology
  2. High renal DC-SIGN+ cell density is associated with severe renal lesions and poor prognosis in patients with immunoglobulin A nephropathy.2019Histopathology
  3. Plasma fractalkine levels are associated with renal inflammation and outcomes in immunoglobulin A nephropathy.2019Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  4. Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy.2018Medicine
  5. [Clinical efficacy of tonsillectomy in renal transplant patients with recurrent IgA nephropathy].2018Zhonghua yi xue za zhi
  6. Decreased DACH1 expression in glomerulopathy is associated with disease progression and severity.2016Oncotarget
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy即将招募NCT06528015牵头方(推断)IV期2024-07 启动
  2. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 1 家医院列在戈谢病下全国有 40 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease已完成NCT05529992研究中心III期2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

尼曼-匹克病 C 型

Niemann–Pick disease type C

2021–2025 年没有牵头尼曼-匹克病 C 型的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 1 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Aberrant activation of Cdc2/cyclin B1 is involved in initiation of cytoskeletal pathology in murine Niemann-Pick disease type C.2017Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 2 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta进行中,不再招募NCT05972551研究中心III期2024-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

武汉有 6 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 13 篇,占 8.1%。

牵头论文
13
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 3320232024: 2220242025: 332025

武汉有 3 家医院列在先天性巨结肠下全国有 76 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室儿科

这些论文过半是实验室或动物研究。

牵头的论文13
  1. Analysis of the causes of redo pull-through for recurrent constipation and the risk factors affecting the prognosis of the Hirschsprung's disease: a single-center retrospective study and systematic review.2025BMC pediatrics
  2. EMB is essential for enteric nervous system development mediated by PI3K signaling.2025Genome medicine
  3. Rare and common genetic variants underlying the risk of Hirschsprung's disease.2025Human molecular genetics
  4. Identification of signaling pathways that specify a subset of migrating enteric neural crest cells at the wavefront in mouse embryos.2024Developmental cell
  5. Mesenchymal Stem Cells Attenuates Hirschsprung diseases - Associated Enterocolitis by Reducing M1 Macrophages Infiltration via COX-2 Dependent Mechanism.2024Journal of pediatric surgery
  6. Screening of undernutrition in children with Hirschsprung disease using preoperative anthropometric parameters: A multicenter cross-sectional study.2023JPEN. Journal of parenteral and enteral nutrition
  7. Abnormally elevated expression of ACTA2 of circular smooth muscle leads to hyperactive contraction in aganglionic segments of HSCR.2023Pediatric surgery international
  8. Comprehensive characterization of the genetic landscape of familial Hirschsprung's disease.2023World journal of pediatrics : WJP
  9. Identification and validation of the common pathogenesis and hub biomarkers in Hirschsprung disease complicated with Crohn's disease.2022Frontiers in immunology
  10. Down-Regulation of Double C2 Domain Alpha Promotes the Formation of Hyperplastic Nerve Fibers in Aganglionic Segments of Hirschsprung's Disease.2022International journal of molecular sciences
  11. Transanal full-thickness pull-through approach in the treatment of anastomotic leakage after operation for Hirschsprung disease.2022Pediatric surgery international
  12. NOX5 is expressed aberrantly but not a critical pathogenetic gene in Hirschsprung disease.2021BMC pediatrics
  13. Benzophenone-3 induced abnormal development of enteric nervous system in zebrafish through MAPK/ERK signaling pathway.2021Chemosphere
早期论文(2016–2020 年)12
  1. Long-term outcomes of single-incision laparoscopic technique in Soave procedure compared with heart-shaped anastomosis for Hirschsprung disease.2020International journal of colorectal disease
  2. Long-term outcomes of laparoscope-assisted heart-shaped anastomosis for children with hirschsprung disease: A 10-year review study.2020Journal of pediatric surgery
  3. Thyroid Hormone in the Pathogenesis of Congenital Intestinal Dysganglionosis.2020Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  4. Optimal time for single-stage pull-through colectomy in infants with short-segment Hirschsprung disease.2019International journal of colorectal disease
  5. Results of rectoanal manometry after a novel laparoscopic technique: laparoscope-assisted heart-shaped anastomosis for Hirschsprung's disease.2019Pediatric surgery international
  6. A Long-Term Follow-Up of a New Surgery Method: Laparoscope-Assisted Heart-Shaped Anastomosis for Hirschsprung's Disease.2018Journal of laparoendoscopic & advanced surgical techniques. Part A
  7. Diagnostic value of the preoperatively detected radiological transition zone in Hirschsprung's disease.2017Pediatric surgery international
  8. A de novo deletion mutation in SOX10 in a Chinese family with Waardenburg syndrome type 4.2017Scientific reports
  9. Novel Insights into the Pathogenesis of Hirschsprung's-associated Enterocolitis.2016Chinese medical journal
  10. Laparoscopy-assisted versus transabdominal reoperation in Hirschprung's disease for residual aganglionosis and transition zone pathology after transanal pull-through.2016Journal of pediatric surgery
  11. Single-incision laparoscopic versus conventional laparoscopic surgery for Hirschsprung's disease: A comparison of medium-term outcomes.2016Journal of pediatric surgery
  12. Pathological changes of interstitial cells of Cajal and ganglion cells in the segment of resected bowel in Hirschsprung's disease.2016Pediatric surgery international
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Nutrition Support for Hirschsprung Disease已完成NCT04598841牵头方不分期2021-01 启动
  2. A Trial on Treatments of Hirschsprung Allied Disease状态不明NCT02212054牵头方不分期2020-05 启动
  3. Comparison of Circular(Soave) and Heart-shaped Anastomosis in Hirschsprung's Disease已完成NCT02234219牵头方不分期2019-11 启动
  4. Fast-track Surgery in the Treatment of Hirschsprung's Disease状态不明NCT02350088牵头方不分期2014-01 启动
  5. A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective Study状态不明NCT02216994牵头方不分期2013-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年没有牵头遗传性大疱性表皮松解症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 1 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

武汉有 1 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
牵头的论文1
  1. Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.2022Orphanet journal of rare diseases
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Phase 2 in Adult Subjects With Hereditary Angioedema进行中,不再招募NCT06846398研究中心II期2025-02 启动
  2. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China已完成NCT06346899研究中心2024-07 启动
  3. A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)已完成NCT05460325研究中心III期2022-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 4 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.9%。

牵头论文
2
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

武汉有 3 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科
牵头的论文2
  1. Clinical follow-up investigation on thickness changes in the peripapillary retinal nerve fibre layer of patients with Leber hereditary optic neuropathy.2024BMC ophthalmology
  2. Characterisation of thickness changes in the peripapillary retinal nerve fibre layer in patients with Leber's hereditary optic neuropathy.2021The British journal of ophthalmology
早期论文(2016–2020 年)10
  1. Factors associated with rapid improvement in visual acuity in patients with Leber's hereditary optic neuropathy after gene therapy.2020Acta ophthalmologica
  2. Multilocus Mitochondrial Mutations Do Not Directly Affect the Efficacy of Gene Therapy for Leber Hereditary Optic Neuropathy.2020Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  3. Seven-Year Follow-up of Gene Therapy for Leber's Hereditary Optic Neuropathy.2020Ophthalmology
  4. What are the characteristics and progression of visual field defects in patients with Leber hereditary optic neuropathy: a prospective single-centre study in China.2019BMJ open
  5. Clinical Observation of Patients with Leber's Hereditary Optic Neuropathy Before Gene Therapy.2018Current gene therapy
  6. Visual Acuity Testing Before and After Intravitreal Injection of rAAV2-ND4 in Patients.2018Methods in molecular biology (Clifton, N.J.)
  7. Visual Field Variability after Gene Therapy for Leber's Hereditary Optic Neuropathy.2018Ophthalmic research
  8. Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy.2016EBioMedicine
  9. Evaluation of Leber's hereditary optic neuropathy patients prior to a gene therapy clinical trial.2016Medicine
  10. Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.2016Scientific reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy状态不明NCT03153293牵头方(推断)II/III期2017-12 启动
  2. Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)已完成NCT01267422牵头方(推断)不分期2011-04 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

华中科技大学同济医学院附属同济医院

Tongji Hospital

武汉

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Tongji Hospital; Tongji Hospital of Tongji Medical College; Affiliated Tongji Hospital; Tongji Hospital Affiliated to Tongji Medical College; Sino-French Branch of Tongji Hospital of Tongji Medical College; Tongji Hospital Affiliated with Tongji Medical College; Tongji Hospital Affiliated to Tongji Medical College of Huazhong; Huazhong University of Science and Technology

提出更正下载数据